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An Assessment of the Role of Chimpanzees in AIDS
Vaccine Research
Jarrod Bailey
New England Anti-Vivisection Society, Boston, MA, USA
Summary — Prior to Simian Immunodeficiency Virus (SIV)-infected macaques becoming the ‘model of
choice’ in the 1990s, chimpanzees were widely used in AIDS vaccine research and testing. Faced with the
continued failure to develop an effective human vaccine, some scientists are calling for a return to their
widespread use. To assess the past and potential future contribution of chimpanzees to AIDS vaccine development, databases and published literature were systematically searched to compare the results of AIDS
vaccine trials in chimpanzees with those of human clinical trials, and to determine whether the chimpanzee
trials were predictive of the human response. Protective and/or therapeutic responses have been elicited in
chimpanzees, via: passive antibody transfer; CD4 analogues; attenuated virus; many types and combinations of recombinant HIV proteins; DNA vaccines; recombinant adenovirus and canarypox vaccines; and
many multi-component vaccines using more than one of these approaches. Immunogenicity has also been
shown in chimpanzees for vaccinia-based and peptide vaccines. Protection and/or significant therapeutic
effects have not been demonstrated by any vaccine to date in humans. Vaccine responses in chimpanzees
and humans are highly discordant. Claims of the importance of chimpanzees in AIDS vaccine development
are without foundation, and a return to the use of chimpanzees in AIDS research/vaccine development is
scientifically unjustifiable.
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Introduction
Over decades, billions of dollars have been dedicated to the development of an AIDS vaccine, only
to result in disappointment and failure (1, 2). The
exact number of vaccines tested pre-clinically and
clinically is difficult to determine, but recent
reviews have suggested over 30–40 vaccines in over
85 clinical trials involving almost 20,000 volunteers
(3–7). The US National Institute of Allergy and
Infectious Diseases (NIAID) report over 50 preventive vaccines in over 100 clinical trials (8), and 30plus therapeutic trials. This analysis indicates that
the figures are even greater, with no vaccine affecting disease progression (9, 10) or approved for use.
Initial optimism, such as that shown in 1984
when the US Health and Human Services secretary
declared that a vaccine would be available within
two years, has given way to a realisation that the
virus will not be beaten easily. In some quarters, it
is acknowledged that animal models of questionable
relevance are culpable (for comprehensive cited
examples and examples of expert opinion, see [11]
and other cited references throughout this review).
These animal models include the use of macaques
infected with Simian Immunodeficiency Virus (SIV)
or hybrids of SIV and Human Immunodeficiency
Virus (HIV). President Clinton’s 2007 goal for the

development of an AIDS vaccine has now passed,
with notable high-profile failures such as VaxGen’s
AIDSVAX and Merck’s V520 vaccines. In 2004, the
AIDS Vaccine Advocacy Coalition (AVAC) acknowledged that there would be no vaccine available by
2007, foreseeing a ‘long haul’ (12); and optimistic
experts predict that it will be over a decade before
the first vaccine is available — while others predict
half a century (13).
In the light of these statistics and recent highprofile failures, many scientists are advocating
changes to AIDS vaccine development. A small
number involved in chimpanzee research believe
that chimpanzees have been, and will remain,
important, and thus advocate a return to their use
(14).
This recommendation requires evidence that
chimpanzees played a crucial role when their use in
the late 1980s and early 1990s was common. This is
the scope of this study: to assess whether their
responses to previous vaccines correlated with
human responses and to compare the immunogenic
and prophylactic natures of those vaccines in chimpanzees and humans. The a priori argument is that
if the vaccines behaved similarly, the resumed use
of chimpanzees may be scientifically justifiable,
independent of ethical considerations; but if the
chimpanzee results proved erroneously predictive,
there would be no scientific basis upon which to call
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for the reinstatement of chimpanzees in AIDS
research.

Summary of Vaccines and Clinical
Trials
A prerequisite for comparing human and chimpanzee responses to AIDS vaccines is a comprehensive assessment of which vaccines have been
involved in clinical trials to date. This was achieved
by consulting the National Library of Medicine’s
ClinicalTrials.gov database (http://www.clinicaltrials.gov/), for which registration of clinical trials has
been required for several years by the International
Committee of Medical Journal Editors. The search
was performed by using the operators ‘AIDS OR
HIV’ (Disease or Condition field), and ‘Vaccine’
(Experimental Treatment field). It included all trials
that were no longer recruiting patients. Though
this database may not constitute an exhaustive
repository of information regarding all trials of HIV
vaccines to date, it currently describes around
47,000 trials sponsored by the National Institutes
of Health (NIH), other US federal agencies and private industry, conducted in 151 countries. For the
purposes of this investigation, it can be regarded as
the most complete source of HIV clinical trial data
which is readily available. The International AIDS
Vaccine Initiative (IAVI) database (http://www.
iavireport. org/trialsdb/default.asp) was also used to
obtain vaccine details.
All the clinical trials located are summarised in
Table 1. The 197 clinical trials of AIDS vaccines

registered involved 85 different vaccine products
(strain specificity of recombinant proteins, for
example, was taken into account, meaning that
strain MN recombinant gp120 was considered to be
a separate vaccine from strain SF-2 recombinant
gp120).
Figure 1 indicates the types and prevalence of
vaccines tested clinically in the 197 trials: 49 trials
(25%) were of recombinant protein vaccines; 41 trials (21%) were of recombinant microbial vaccines
(RMVs); and 50 trials (25%) used a combination of
two or more approaches. These trials and the others
constituting the remaining 29%, are discussed
below.
Figure 2 provides a breakdown of the types of
vaccines in the RMV class. Of 41 trials, 13 (32%)
involved canarypox vectors, closely followed by adenovirus vectors (12 trials [29%]). Eight trials (20%)
were based on vaccinia virus vaccines, and the
remaining 19% involved a variety of viruses and
bacteria, as detailed in the text.
Of the trials, 143 (72%) were Phase I trials
(Figure 3), which involve a relatively small number
of volunteers (typically 20–100) over a two-year
period, in which humans encounter the vaccine for
the first time. Twenty-four (12%) were Phase II trials, in which vaccine candidates that appeared
promising in Phase I investigations are tested in up
to 300 people, including those at high risk of HIV
infection or who are HIV-positive (HIV+). Sixteen
(8%) Phase I/II trials were also registered (i.e.
Phase I and Phase II trials performed in parallel).
Just seven of the 197 clinical trials progressed to
Phase III (the final stage of testing prior to licens-

Figure 1: AIDS vaccines in clinical trials
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A total of 197 trials were registered with ClinicalTrials.gov, up to and including 11 November 2007.
Mixed = combinations of two or more vaccines; inact. virus = inactivated virus vaccines; rec. protein = recombinant
protein vaccines; VLP = virus-like particles; DNA = DNA-based vaccines; RMVs = recombinant microbial vaccines;
aut. cells = autologous cell vaccines.
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Figure 2: RMV vaccines in clinical trials
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Up to and including 11 November 2007, 41 trials involving recombinant microbial vectors were conducted, as
identified by ClinicalTrials.gov. Multiple = combinations of two or more RMV vaccine types; AAV = adeno-associated
virus; VEEA = Venezuelan Equine Encephalitis alphavirus; S. typhi = Salmonella typhi.

ing), in which the vaccine is tested typically in up to
3000 people, involving individuals at higher risk. A
further seven trials did not specify the phase.
Figure 4 summarises the status of the registered
trials as of summer 2007. A total of 106 trials (54%)
had reached an end, of which 95 trials (48% of the
total) had been completed, with a further ten terminated and one suspended. Fifty-eight trials (29%)
were ‘no longer recruiting’; 33 were either actively,
or about to begin, recruiting (24 trials and nine trials, respectively).

Detailed Analysis and Human Versus
Chimpanzee Comparison
Vaccines and clinical trials were analysed in detail
to assess whether those that failed in humans provided protection from HIV infection and/or therapeutic benefits in chimpanzees. A comprehensive
analysis was performed of the recent history and
current situation surrounding vaccine development
in chimpanzees (see Table 2 for trial information)
and humans (Table 1), and to compare results and
information from each species. Full use was made of
the Nonhuman Primate HIV/SIV Vaccine Trials
(NHPVT) Database (http://www.hiv.lanl.gov/content/
vaccine/home.html). In these Tables, the interventions are shown in plain text, underlined, or bold
text, to indicate which specific vaccines were tested
in both species (see Table legends).

Passive approaches
Many of the early experiments in HIV vaccine
research centred on passively transferring HIV and
SIV-specific antibodies from infected to noninfected animals, to see if this protected the recipients from infection following a subsequent viral
challenge (for reviews, see 15–19). Five such trials
in chimpanzees are registered in the NHPVT database, and are summarised in Table 2.
The search of the ClinicalTrials.gov database did
not locate any human trials of passive antibodies to
protect against or to treat HIV infection, but many
reports of pre-clinical and clinical investigations of
passive therapies for HIV/AIDS do exist. The
NHPVT database contains five entries for trials of
this type, and all but the earliest (NHP .361; registered in 1988) either prevented or controlled HIV
infection in chimpanzees (Table 2). Murthy et al.
(17) referred to passive immunisation studies in
chimpanzees involving a total of five different antibodies. Four of them were protective; the one that
was not protective did, however, delay the onset of
infection (20). HIV human hyperimmune immunoglobulin (HIVIG) had been shown to protect chimpanzees from HIV challenge when administered
both pre- and post-exposure (21), an observation
that prompted the authors to conclude that induction of humoral immunity was a pre-requisite for
any HIV vaccine, but that cell-mediated immunity
may not be needed — a conclusion that is
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Figure 3: Phases of AIDS vaccine clinical
trials
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Percentage of vaccine candidates in different phases of
clinical trials, as of 11 November 2007.
Not classified = phase not specified. N = 197.

unfounded in humans. Stiehm et al. (22), in contrast, assessed the effects of HIVIG in 30 HIV+ children, where CD4 cell levels, plasma RNA copy
number, cellular virus load, immunoglobulin levels,
and neutralising antibody titres were only minimally affected and clinical status was not changed.
A soluble CD4 analogue called ‘CD4-IgG’ (also
known as CD4 immunoadhesin, in which CD4 is
combined with an immunoglobulin for stability)
was also protective in chimpanzee experiments
(23). Trials in humans, however, suggested no evidence of clinical benefit: for example, a Phase I trial
revealed that CD4-IgG did not augment the effects
of the HIV inhibitor drug, azidothymidine (AZT;
24), and a Phase I/II investigation revealed a slight
improvement of T-helper cell function, but no clinical benefit (25). Arguably, these difficulties may be
expected, because HIV+ individuals have high levels of soluble CD4 in their blood, even in quite
advanced AIDS, suggesting it has little or no effect
on progression of the disease.
More recently, Armbruster et al. (26, 27)
described Phase I clinical trials of three human
monoclonal antibodies (hMAbs), in which they were
safe and well tolerated. One of these antibodies had
been shown to delay seroconversion in chimpanzees
some time previously (16), and a paper reported a
proof-of-principle human study (though the evidence is considered to be ‘circumstantial’; 28),
showing that a cocktail of the same hMAbs could

Live attenuated virus vaccines have historically
been used with great success against many diseases
(including measles, mumps and rubella), due to
their induction of strong and broadly reactive
humoral and cell-mediated immune responses (31).
Despite this, putative AIDS vaccines of this class
have been limited to NHP studies and have not
entered clinical trials (32, 33). This is due to concerns over reversion to virulence, recombination
with other virions to form new, potentially highly-

Figure 4: Status of AIDS vaccine clinical
trials
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were major caveats, however: the trial was neither
randomised nor blinded; only two of eight chronically infected patients showed rebound delay; the
antibodies used had to be highly potent and used at
a high dose; and, there was evidence of rapid escape.
Nevertheless, in spite of these caveats, it is claimed
that the findings from these experiments, in which
the transferred antibodies protected chimpanzees
against HIV-1 infection when administered immediately prior to or after viral challenge, directed the initial push toward an HIV vaccine involving
recombinant HIV envelope proteins to induce the production of HIV neutralising antibodies (29, 30). The
status of this approach to vaccine development is considered in detail below (see ‘Recombinant Proteins’).
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Summary of the status of registered clinical trials of
AIDS vaccines, as of 11 November 2007.
R/NYR = trials recruiting or not yet recruiting;
NLR = trials no longer recruiting; C/T/S = completed,
terminated or suspended trials. N = 197.
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pathogenic strains, and the dangerous consequences of integration of the attenuated virus
genetic material into the host genome (summarised
by Van der Ryst; 29). Although these concerns are
largely based on the results of macaque experiments, there are convincing human data: immunosuppression has occurred in humans exposed to
attenuated HIV via blood transfusions; and residual
infectivity caused over 200,000 people to be infected
by live polio virus during vaccination in the infamous Cutter incident (30).
Inactivated AIDS vaccines, however, have been
tested clinically. Ten trials are registered, including
two in 2005 for the Remune vaccine (formerly
known as HIV-1 Immunogen), which comprises
whole HIV particles that have been chemically and
radioactively inactivated, with their envelopes
removed to preclude the infection of T-cells. The
rationale is to use this vaccine as a therapeutic
intervention, probably in tandem with anti-retroviral drugs, in people already infected with HIV, in
order to control the activity of the virus by stimulating cell-mediated immunity and thus reduce the
rate of progression of AIDS.
However, Remune has failed to produce promising
results in human subjects. Two of the ten trials (the
most recent of which was registered in 2005) were
terminated, and a large Phase III study failed to find
any additional benefit from Remune, when used to
augment anti-HIV drugs (10). Even more recently in
July 2007, Remune’s manufacturer (Immune
Response Corporation) announced the discontinuation of its HIV Vaccine Development Program altogether, following a disappointing clinical trial of
Remune and its second-generation successor vaccine,
IR103 (consisting of Remune and an adjuvant known
as Amplivax) (34). The results of human trials have
therefore prompted negative opinions concerning this
approach in a number of reviews, for example,
“…inactivated viruses have not been capable of
inducing adequate immunoresponse” (35).
There is evidence of enhanced immune response
in chimpanzees following vaccination with a gp120depleted inactivated HIV-1 (36), and the NHPVT
database contained one record of a chimpanzee trial
of this type of vaccine (Table 2). In 1993, inactivated whole HIV-1 was tested along with three different adjuvants (37), in three groups of three
chimpanzees — but even the group with the ‘best’
immune responses became infected when challenged shortly after their sixth immunisation. It is
therefore assumed that vaccines of this type may
have proceeded to clinical trials based on more-positive results from experiments with other species.

Recombinant proteins
Immunogenic proteins have constituted a significant area of AIDS vaccine research, accounting for
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49 (25%) of the 197 registered trials, though just
seven of them have been registered since 2004.
These 49 trials have tested just nine different vaccines (or 15 vaccines, if similar proteins from different strains of HIV are included). Vaccines tested
have comprised the following: gp160 (expressed in
Vero cells [epithelial cells from African green monkeys], in Sf9 cells by using recombinant baculovirus, and from strains IIIB and LAI-2); gp120
(strains SF2, MN, IIIB, A244 and W61D, and also
Env 2-3 [a yeast-derived gp120 combined with an
adjuvant emulsion]); NefTat fusion protein; Tat
protein; EnvPro (an engineered and stabilised form
of gp160 with adjuvant); and p24 protein (from the
gag gene). Other proteins, such as the viral polymerase and regulatory proteins Rev and Vpr, have
also been subject to evaluation. Perhaps the bestknown candidate vaccines from this class are the
AIDSVAX vaccines (AIDSVAX B/B and AIDSVAX
B/E), each comprising two gp120 proteins from different HIV clades.
The relatively high number of trials for the number of recombinant protein vaccines is due to combination of the immunogenic proteins with a
variety of adjuvants, as well as the testing of different routes of administration. Notably, just nine
of the total of 49 trials have not been completed. Of
the 40 completed trials, just four had progressed
beyond Phase I. Of the nine trials that had not
been completed, three were prematurely terminated. Almost all of the trials (45/49) involved
recombinant envelope protein, since this protein is
the primary target for neutralising antibodies in
infected persons (38). Although invariably
immunogenic, the antibodies induced have tended
to be very clade-specific and have failed to neutralise primary isolates of HIV derived from the
blood of patients. Another major problem with the
use of stand-alone vaccines of this type was quickly
revealed — they rarely induced the cell-mediated
arm of the immune system, which has been
regarded as an essential requirement for an HIV
vaccine for some years (39).
Seven chimpanzee trials of recombinant proteins were listed in the NHPVT database, in
which eight vaccines were tested (Table 2). All
eight tests showed the vaccines to be immunogenic (though one test gave mixed results). Three
of the eight tests did not result in protection
(involving two gp120 and one gp160 vaccine),
whereas three tests did result in protection (all of
which involved gp120 vaccines). One of the tests
(with a gp120 vaccine) gave mixed results (where
one animal was protected, but another was not
protected completely), and another test did not
assess protection from infection.
Notable vaccines reported in the scientific literature include recombinant gp120 vaccines that protected chimpanzees from subsequent challenge
(40–42), but that failed to show protection in

Trial ID

Official title

NCT00000943

NCT00001445

NCT00002172

NCT00002173

NCT00002359

NCT00005001

NCT00005002

NCT00006153

NCT00021762

NCT00238459

1999

1999

1999

1999

1999

2000

2000

2000

2005

2005

Immunopathogenesis of acute and early HIV infection and the role of HIVspecific CD4 T-cell responses and the effect of their enhancement by potent
antiretroviral drugs and an HIV vaccine

Effects of immunisation with HIV-1 immunogen plus anti-HIV treatment
interruption on the levels of HIV

Effectiveness of adding Remune to the current anti-HIV drug combination

A randomised, double-blind, adjuvant-controlled, multicentre study to compare
the virologic and immunologic effect of HAART plus Remune versus HAART
plus (IFA) in antiretroviral-naïve patients infected with Human
Immunodeficiency Virus Type 1 (HIV-1)

A pilot, phase II, double-blind study to assess the virologic effect of Remune
versus IFA in patients who are infected with Human Immunodeficiency Virus
Type 1 (HIV-1), have a plasma HIV-1 RNA level less than 50 copies/ml, are
receiving Highly Active Antiretroviral Therapy (HAART), and who subsequently
discontinue their HAART regimen

A multicentre, double-blind, phase III, adjuvant-controlled study of the effect of
10 units of HIV-1 immunogen (Remune) compared to IFA alone every 12 weeks
on AIDS-free survival in subjects with HIV infection and CD4 T-lymphocytes
between 300 and 549 cells/µl regardless of concomitant HIV therapies

An expanded access, open-label protocol of Remune (HIV-1 immunogen) in HIV1-infected adults with CD4 count 550 cells/ml and greater

An expanded access, open-label, compassionate use protocol of Remune in HIV1-infected adults with CD4 count less than 300 cells/ml

Phase I study to evaluate the safety and immunogenicity of HIV-1 immunogen
in children with HIV-1 infection

A study to test if giving Remune (an HIV vaccine) can improve the immune
systems of HIV-positive patients who are also participating in ACTG 328

Attenuated/inactivated virus

Date
reg’d

Table 1: Clinical trials of AIDS vaccines listed in the ClinicalTrials.gov database
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HIV-1 immunogen (Remune)

HIV-1 immunogen (gp120depleted inactivated HIV-1
preparation in Incomplete
Freund’s Adjuvant (IFA)
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Trial ID

NCT00000633

NCT00000667

NCT00000745

NCT00000749

NCT00000755

NCT00000757

NCT00000762

1999

1999

1999

1999

1999

1999

1999

A placebo-controlled, phase I clinical trial to evaluate the safety and
immunogenicity of recombinant envelope proteins of HIV-1 gp160 and gp120 in
children ≥ 1 month old with asymptomatic HIV infection

A phase I multicentre trial to evaluate the safety and immunogenicity of HIV-1
recombinant envelope glycoprotein gp160

A phase I/II trial of vaccine therapy of HIV-1 infected individuals with 50–500
CD4 cells/mm3

A phase I clinical trial to evaluate the safety and immunogenicity of 200µg of
gp120 (CHO) BIOCINE in MF59 emulsion versus the emulsion control: three
injections at 0, 1, and 6 months

A phase I multicentre, randomised, double-blind, placebo-controlled trial to
evaluate the safety and immunogenicity of HIV-1 recombinant envelope
glycoprotein gp160

A phase I/II dose escalation study of intradermal gp160 to evaluate safety,
delayed type hypersensitivity (skin test) responses and immunogenicity in
asymptomatic HIV seropositive patients with more than 400 CD4+ cells

A phase I multicentre clinical trial to evaluate the safety and immunogenicity
of Immuno-AG recombinant HIV gp160 in asymptomatic HIV seropositive
individuals

A phase I clinical trial to evaluate the safety and immunogenicity of 100µg of
Env 2-3 in MF59

Official title

rgp120/HIV-1MN
rgp120/HIV-1 SF-2
gp160 vaccine
(MicroGeneSys)

gp160 vaccine
(MicroGeneSys)

rgp120/HIV-1MN

rgp120/HIV-1 SF-2

gp160 vaccine
(MicroGeneSys)

gp160 vaccine
(MicroGeneSys)

gp160 vaccine
(Immuno-AG)

Env 2-3

Interventions

I

I

I

I

I

I

I

I

Phase

C

C

C

C

C

C

C

C

Status

T

P

T

P

P

T

T

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

NCT00000632

1999

Recombinant protein

Date
reg’d

Table 1: continued

Role of chimpanzees in AIDS vaccine research
387

Trial ID

NCT00000774

NCT00000777

NCT00000779

NCT00000782

NCT00000809

NCT00000822

NCT00000832

NCT00000853

NCT00000956

NCT00000957

Date
reg’d

1999

1999

1999

1999

1999

1999

1999

1999

1999

1999

Table 1: continued

A phase I multicentre clinical trial to evaluate the safety and immunogenicity
of vaccinia derived HIV-1 recombinant envelope glycoprotein (gp160) of
Human Immunodeficiency Virus: Evaluation of accelerated schedules

A phase I multicentre trial to evaluate the safety and immunogenicity of HIV-1
recombinant envelope glycoprotein gp160

A phase I, multicentre, randomised, double-blind, placebo-controlled HIV-1
vaccine trial to evaluate the safety and immunogenicity of low dose MN
rsgp120/HIV-1 (Genentech) in combination with QS21 adjuvant or alum in
healthy adults

A randomised, placebo-controlled, double-blinded phase I safety and
immunogenicity trial of recombinant envelope protein, HIV-1 SF-2 rgp120
(BIOCINE), combined with MF59 in HIV-1 uninfected adult volunteers

A phase I/II double-blind controlled trial to determine the safety and immunogenicity of HIV-1 MN rgp160 Immuno-AG vaccine therapy in HIV-infected
individuals with ≥ 500/mm3 CD4+ T-cells and 200–400/mm3 CD4+ T-cells

Safety and effectiveness of two different formulations of an HIV vaccine in
infants born to HIV-infected women

A phase I/II study of Delayed-Type Hypersensitivity (DTH) reactions to
intradermal HIV envelope antigen

A phase I comparative blinded trial of several HIV-1 derived immunogens in
infected individuals with ≥ 500 CD4 cells/mm3

Active immunisation of HIV-1 infected, pregnant women with CD4 lymphocyte
counts ≥ 400/mm3: A phase I study of safety and immunogenicity of VaxSyn
recombinant gp160 (Note: some patients receive placebo)

A phase I study to evaluate the safety and immunogenicity of recombinant
HIV-1 envelope antigen in children born to HIV-infected mothers

Official title

gp160 vaccine
(Immuno-AG)

gp160 vaccine
(MicroGeneSys)

rgp120/HIV-1MN

rgp120/HIV-1 SF-2

gp160 vaccine
(Immuno-AG)

MN rsgp120/HIV-1

gp160 vaccine
(Immuno-AG)
gp160 vaccine
(MicroGeneSys)

rgp120/HIV-1IIIB
rgp120/HIV-1MN
rgp120/HIV-1 SF-2
Env 2-3

gp160 vaccine
(MicroGeneSys)

rgp120/HIV-1MN
rgp120/HIV-1 SF-2

Interventions

I

I

I

I

I

I

I

I

I

I

Phase

C

C

C

C

C

T

C

C

C

NLR

Status

P

P

P

P

T

T

T

T

P/T

P/T

Preventive/
therapeutic
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NCT00000958

NCT00000968

NCT00000972

NCT00000977

NCT00001019

NCT00001020

NCT00001021

1999

1999

1999

1999

1999

1999

1999

A phase I multicentre study of the safety and immunogenicity of MN
rgp120/HIV-1 vaccine given either alone or in combination with IIIB
rgp120/HIV-1 vaccine in healthy adult subjects (Note: original study extended
only for patients previously enrolled on VEU 009)

A phase I study of the safety and immunogenicity of rgp120/HIV-1IIIB vaccine
in healthy adult subjects (Note: study extended only for subjects who have
previously received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or
VEU 006 rollover study)

Safety of and immune response to an HIV vaccine (SF-2 gp120) with or without
MTP-PE/MF59 adjuvant

Active immunisation of asymptomatic, HIV-infected individuals with
recombinant gp160 HIV-1 antigen: A phase I/II study of immunogenicity and
toxicity

A phase I clinical trial to evaluate:
Part A. The safety of MTP-PE/MF59 adjuvant emulsion
Part B. The safety and immunogenicity of Env 2-3, a yeast-derived recombinant
envelope protein of HIV-1, in combination with MTP-PE/MF59

A phase I multicentre clinical trial to evaluate the safety and immunogenicity of
vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160)

A placebo-controlled, phase I, pilot clinical trial to evaluate the safety and
immunogenicity of Env 2-3, a yeast-derived recombinant envelope protein of
HIV-1, in combination with MTP-PE/MF59 in individuals with HIV infection
(placebo patients receive MF59 emulsion only)

Official title

rgp120/HIV-1IIIB
rgp120/HIV-1MN

rgp120/HIV-1IIIB
rgp120/HIV-1MN

rgp120/HIV-1 SF-2

gp160 vaccine
(MicroGeneSys)

Env 2-3

gp160 vaccine
(Immuno-AG)

Env 2-3

Interventions

I

I

I

I

I

I

I

Phase

C

C

C

C

C

C

C

Status

P

P

P

T

P

P

T

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

Trial ID

Date
reg’d
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Trial ID

NCT00001031

NCT00001037

NCT00001041

NCT00001042

NCT00001043

NCT00001044

NCT00001046

NCT00001052

NCT00001056

Date
reg’d

1999

1999

1999

1999

1999

1999

1999

1999

1999

Table 1: continued

A phase I multicentre clinical trial to evaluate the safety and immunogenicity
of vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) of human
immunodeficiency virus: Evaluation of a 200µg dose

A phase I, multicentre, randomised, double-blind, placebo-controlled HIV-1
vaccine trial to evaluate the safety and immunogenicity of MN recombinant
soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in combination with QS21
adjuvant and/or alum in healthy adults

Active immunisation of HIV-infected pregnant women: A phase I study of safety
and immunogenicity of a rgp120/HIV-1 vaccine (Note: some patients receive
placebo)

A phase I, multicentre, randomised, double-blind, placebo-controlled HIV-1
vaccine trial to evaluate the safety and immunogenicity of rgp120/HIV-1MN
(Genentech) in combination with QS21 adjuvant and/or alum in healthy adults

A phase I, multicentre, randomised trial to evaluate the safety and
immunogenicity of vaccinia-derived MN HIV-1 recombinant envelope
glycoprotein (rgp160) of human immunodeficiency virus at two different
vaccination schedules

A phase I, randomised, double-blind, placebo-controlled, clinical trial to compare
the safety and immunogenicity of recombinant envelope protein
rgp120/HIV-1SF2 (BIOCINE) combined with seven adjuvants in healthy HIV-1
uninfected individuals

Active immunisation of HIV-1 infected, pregnant women with CD4 lymphocyte
counts ≥ 400/mm3: A phase I study of safety and immunogenicity of MN
rgp120/HIV-1 vaccine (Note: some patients receive placebo)

A phase I, multicentre, clinical trial to evaluate the safety and immunogenicity
of vaccinia-derived MN HIV-1 recombinant envelope glycoprotein (rgp160) of
HIV at two different vaccination schedules

A phase II clinical trial to evaluate the immunogenicity and reactogenicity of
the recombinant HIV-1 envelope vaccines SF-2 rgp120 (CHO) [Chiron vaccines]
in MF59 adjuvant and MN rgp120/HIV-1 [VaxGen] in alum adjuvant in healthy
adults

Official title

gp160 vaccine
(Immuno-AG)

rgp120/HIV-1MN

rgp120/HIV-1 SF-2

rgp120/HIV-1MN

gp160 vaccine
(Immuno-AG)

rgp120/HIV-1 SF-2

rgp120/HIV-1MN

gp160 vaccine
(Immuno-AG)

rgp120/HIV-1MN
rgp120/HIV-1 SF-2

Interventions

I

I

I

I

I

I

I

I

II

Phase

C

C

T

C

C

C

C

C

C

Status

P

P

T

P

P

P

T

P

P

Preventive/
therapeutic

390
J. Bailey

NCT00001096

NCT00001992

NCT00002204

NCT00002402

NCT00002441

NCT00006327

NCT00027365

1999

1999

1999

1999

1999

2000

2001

An investigational combination vaccine given to people who are not infected
with HIV

A phase III trial to determine the efficacy of AIDSVAX B/E vaccine in
intravenous drug users in Bangkok, Thailand

A phase III trial to determine the efficacy of bivalent AIDSVAX B/B vaccine in
adults at risk of sexually transmitted HIV-1 infection in North America

A phase I/II trial to evaluate the safety and immunogenicity of AIDSVAX B/B and
B/E vaccines in the USA

A phase I, observer-blind, placebo-controlled study of the chiron vaccine HIV
p24/MF59 administered to healthy HIV-seronegative adults

A phase I study of the safety and immunogenicity of rgp120/HIV-1IIIB vaccine
in HIV-1 seropositive adult volunteers

A phase I, multicentre, randomised, double-blind, placebo-controlled trial to
evaluate the safety and immunogenicity of HIV-1 MN rsgp120 and bivalent
AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in combination with QS-21
with or without alum in healthy HIV-1 uninfected adults

Official title

Combination vaccine
(NefTat and gp120 W61D)
NefTat
gp120 W61D

AIDSVAX B/E (MN
rgp120/HIV-1 and A244
rgp120/HIV-1)

AIDSVAX B/B (MN
rgp120/HIV-1 and GNE8
rgp120/HIV-1)

AIDSVAX B/B and
AIDSVAX B/E (MN
rgp120/HIV-1 and GNE8
rgp120/HIV-1) and (MN
rgp120/HIV-1 and A244
rgp120/HIV-1)

HIV p24/MF59

rgp120/HIV-1IIIB

MN rgp120/HIV-1 and
A244 rgp120/HIV-1
rgp120/HIV-1MN

Interventions

I

III

III

I/II

I

I

I

Phase

NLR

C

C

C

C

C

NLR

Status

P

P

P

P

P

P

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

Trial ID

Date
reg’d
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A phase I safety and immunogenicity trial of recombinant HIV-1 tat protein in
HIV-1 uninfected adult volunteers

NCT00505401

2007

2007 NCT00529698
(comp.
2004)

NCT00000775

NCT00000795

1999

1999

Peptide/Lipopeptide

A phase I safety and immunogenicity trial of recombinant HIV-1 tat in HIV-1
infected adult volunteers

NCT00412477

2006

A phase I safety and immunogenicity trial of UBI multivalent HIV-1 peptide
immunogen in HIV-1 seronegative human subjects

A phase I safety and immunogenicity trial of UBI SynVac (HIV-1 MN octameric
V3 peptide vaccine)

A phase I study of safety and immunogenicity of the WRAIR HIV-1 vaccine
LFn-p24 administered by the intramuscular (IM) route in healthy adults

A phase I, open-label, parallel group trial to evaluate safety and immunogenicity
of three nasal immunisations using a fixed dose-level of HIV gp140 V2 loop
deleted protein adjuvanted with LTK63 followed by intramuscular boosting with
HIV gp140 V2 loop deleted protein adjuvanted with MF59 when administered
to healthy adults

A phase I, randomised, double-blind clinical trial of the HIV gp120/NefTat/
AS02A vaccine candidate in subjects with well-controlled chronic HIV-1
infection on HAART

NCT00369031

NCT00117429

2005

Safety of the EnvPro HIV vaccine in healthy volunteers

2006

NCT00076947

2004

The effectiveness of human antibodies in influencing an AIDS-like disease in
monkeys

Phase I study evaluating the systemic and mucosal safety and immunogenicity
of a recombinant HIV-1 gp160 (MN/LAI) administered by transmucosal (nasal
or vaginal) routes, alone or formulated with DC-Chol, in HIV negative
volunteers (ANRS VAC14)

NCT00031109

2002

Official title

2005 NCT00122564
(comp.
2003)

Trial ID

Date
reg’d
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HIV-1 peptide immunogen,
multivalent

rgp120/HIV-1MN
Monovalent octameric V3
peptide vaccine

Biologically active
recombinant Tat protein
(ISSP-001)

Recombinant HIV-1 Tat
protein

HIV LFn-p24

Human Immunodeficiency
Virus glycoprotein 140
(vaccine)

HIV-1 gp160

HIV gp120/NefTat/AS02A
vaccine

EnvPro

gp160 MN/LAI-2

Interventions

I

I

I

I

I

I

I

I

I

—

Phase

C

C

C

C

C

NLR

T

R

C

NLR

Status

P

P

P

T

P

P

P

T

P

P

Preventive/
therapeutic
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J. Bailey

NCT00000798

NCT00000845

NCT00000846

NCT00000886

NCT00001060

NCT00001386

NCT00002353

NCT00005779

NCT00076037

1999

1999

1999

1999

1999

1999

1999

2000

2004

Safety of and immune response to a new HIV CTL MEP

Safety of the candidate vaccine C4-V3 alone or with interleukin-12 (IL-12) in
HIV-infected patients receiving effective anti-HIV drug therapy

A phase I safety and immunogenicity trial of UBI HIV lipopeptide
immunotherapeutic P3C541b in HIV-1 seropositive human subjects

Phase I protocol for the evaluation of the safety and immunogenicity of
vaccination with synthetic HIV envelope peptides in patients with early human
immunodeficiency virus infection

A phase I trial of HIV-1 C4-V3 polyvalent peptide vaccine in HIV-1 infected
persons

A phase I safety and immunogenicity trial of HIV-1 gp120 C4-V3 hybrid
polyvalent peptide immunogen mixed in mineral oil containing mannose
mono-oleate (IFA)

A phase I trial to evaluate the safety and immunogenicity of the UBI HIV-1MN
PND peptide immunogen, given by IM injection, in combination with the UBI
microparticulate monovalent HIV-1 MN branched peptide given orally, in
HIV-1 uninfected volunteers

A phase I safety and immunogenicity trial of UBI HIV lipopeptide vaccine
component P3C541b in HIV-1 seronegative human subjects

A phase I safety and immunogenicity trial of UBI microparticulate monovalent
HIV-1 MN peptide immunogen in HIV-1 seronegative human subjects

Official title

HIV CTL MEP

HIV-1 C4-V3 polyvalent
peptide vaccine

P3C541b lipopeptide

PCLUS 3-18 MN
PCLUS 6.1 MN

HIV-1 C4-V3 polyvalent
peptide vaccine

HIV-1 C4-V3 polyvalent
peptide vaccine

HIV-1 peptide vaccine,
microparticulate monovalent
HIV-1 peptide immunogen,
multivalent

P3C541b lipopeptide

HIV-1 peptide vaccine,
microparticulate monovalent

Interventions

I

I

I

I

I

I

I

I

I

Phase

NLR

C

C

C

C

C

C

C

C

Status

P

T

T

T

T

P

P

P

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

Trial ID

Date
reg’d
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NCT00121758

NCT00195234

NCT00381875

2005

2005

2006

NCT00001053

1999

NCT00001088

NCT00001538

NCT00002231

NCT00002232

1999

1999

1999

1999

DNA vaccines

NCT00000835

1999

Virus-like particles

Trial ID

Date
reg’d

Table 1: continued

GENEVAX-HIV (APL 400-003), a candidate DNA vaccine: A pilot study of
GENEVAX-HIV given by intramuscular or intradermal administration in HIV
seronegative volunteers

GENEVAX-HIV (APL 400-003), a candidate DNA vaccine: A pilot dose escalation
study of GENEVAX-HIV delivered intramuscularly using the Biojector 2000 in
HIV seronegative volunteers

A phase I study of APL 400-003, a candidate HIV vaccine, in HIV-negative
volunteers

A phase I safety and immunogenicity trial of the facilitated HIV-1 Gag-Pol DNA
vaccine (APL-400-047, Apollon, Inc.) given intramuscularly by needle and
syringe or Biojector 2000 needle-free jet injection system in HIV-1 uninfected
adult volunteers

A phase I safety and immunogenicity study of HIV p17/p24:Ty-VLP in HIV-1
seronegative subjects

A multicentre, randomised, placebo-controlled, double-blind trial to evaluate
the safety and immunogenicity of an HIV-1 pseudovirion vaccine

A pilot study to investigate the safety and immunogenicity of a peptide vaccine
for HIV infected HLA-A2 individuals designed to impede the development of
antiretroviral resistance

A phase I multicentre, randomised, double-blind, placebo-controlled trial to
evaluate the safety and immunogenicity of an HIV CTL multi-epitope peptide
vaccine formulated with RC529-SE and GM-CSF given to HIV-1 positive adults
on stable HAART

Randomised double-blinded phase II AIDS vaccine study comparing
immunogenicity and safety of 3 doses of lipopeptide (LIPO-5) versus placebo in
non-infected HIV volunteers (ANRS VAC 18)

Official title

GENEVAX-HIV
(APL 400-003)

GENEVAX-HIV
(APL 400-003)

APL 400-003

APL 400-047

HIV p17/p24:Ty-VLP

HIV-1 pseudovirion vaccine

E1M184V peptide vaccine

HIV CTL MEP

LIPO-5

Interventions

I

I

I

I

I

I

I

I

II

Phase

C

C

C

NLR

C

T

R

C

NLR

Status

P

P

P

P

P

P

T

T

P

Preventive/
therapeutic

394
J. Bailey

NCT00002350

NCT00009685

NCT00043511

NCT00045838

NCT00047931

NCT00052182

NCT00054860

NCT00069030

NCT00071851

NCT00089531

1999

2001

2002

2002

2002

2003

2003

2003

2003

2004

Candidate HIV vaccine

Safety of and immune response to an HIV-1 DNA vaccine (VRC
HIVDNA009-00-VP) in HIV uninfected adults

A phase I clinical trial to evaluate the safety and immunogenicity of the HIV-1
DNA vaccine VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env) with the
plasmid cytokine adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig)

Safety of and immune system response to an HIV vaccine (EP HIV-1090) in
HIV uninfected adults

Safety of and immune system response to an HIV vaccine (EP HIV-1090) in
HIV infected patients

A phase I clinical trial to evaluate the safety and immunogenicity of a multiclade
HIV-1 DNA plasmid vaccine, VRC-HIVDNA009-00-VP, in uninfected adult
volunteers

HIV-1 vaccine test in uninfected adult volunteers

Safety of an HIV DNA vaccine given to HIV uninfected adults

HIV-1 vaccine test in uninfected adult volunteers

A phase I trial of APL 400-003 vaccine: Safety and immune response evaluations
of multiple injections at escalating doses in asymptomatic HIV infected patients

Official title

VRC-HIVDNA016-00-VP

VRC-HIVDNA009-00-VP

VRC-HIVDNA009-00-VP
(Gag-Pol-Nef-multiclade Env)

EP HIV-1090

EP HIV-1090

VRC-HIVDNA009-00-VP

VRC-HIVDNA006-00-VP

pGA2/JS2

VRC4302

APL 400-003

Interventions

I

I/II

I

I

I

I

I

I

I

I

Phase

NLR

C

NLR

C

C

NLR

C

C

C

C

Status

P

P

P

P

T

P

P

P

P

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

Trial ID

Date
reg’d
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NCT00532974

A phase I safety and immunogenicity study of the Pharmexa-Epimmune HIV-1
CTL epitope-based DNA vaccine (EP HIV-1090) administered using a Biojector
2000 needle-free immunisation device in HIV-1 infected individuals receiving
potent Combination Antiretroviral Therapy

A phase I clinical trial to evaluate the safety and immunogenicity of PENNVAX-B
(Gag, Pol, Env) given alone, with IL-12 DNA, or with a dose escalation of IL-15
DNA, in healthy, HIV-1 uninfected adult participants

2007

A phase I multicentre, randomised, double-blind, placebo-controlled trial to
evaluate the safety and immunogenicity of an HIV-1 gag DNA vaccine
administered alone or with escalating doses of IL-12 DNA or IL-15 DNA
molecular adjuvants to HIV-1 positive adults receiving stable HAART

NCT00528489

NCT00195312

2005

Evaluation of the tolerability and safety of a recombinant HIV-1 multi-envelope
DNA plasmid vaccine (EnvDNA) in healthy adults

2007

NCT00187148

2005

Safety of and immune response to the experimental preventive HIV vaccine,
EP HIV-1090, in healthy, HIV-1 uninfected adults

A phase I/II, randomised, double-blind study to evaluate the safety, tolerability,
and immunogenicity of LC002, a DermaVir vaccine, in HIV-1 infected subjects
currently under treatment with HAART

NCT00141024

2005

Safety of and immune response to a DNA HIV vaccine (VRC-HIVDNA009-00-VP)
in HIV infected individuals with acute HIV infection

NCT00270205

NCT00125099

2005

EP1090

PennVax B(Gag, Pol, Env)

LC002

I

I

I/II

I

I

HIV-1 gag DNA

ADVAX e/g
ADVAX p/n-t (ADVAX)

I

I

I/II

EnvDNA

EP HIV-1090

VRC-HIVDNA009-00-VP

I

HIV-1 gag DNA

A phase I clinical trial to evaluate the safety and immunogenicity of HIV-1 gag
DNA vaccine alone or with IL-15 DNA, boosted with HIV-1 gag DNA + IL-15
DNA or HIV-1 gag DNA + IL-12 DNA, in healthy, HIV-1 uninfected adult
participants

2005

NCT00115960

2005

I

HIV-1 gag DNA

A phase I clinical trial to evaluate the safety and immunogenicity of an HIV-1
gag DNA vaccine with or without IL-12 DNA adjuvant, boosted with homologous
plasmids in healthy, HIV-1 uninfected adult participants

A randomised, placebo-controlled, dose-escalating, double-blinded phase I study
to evaluate the safety and immunogenicity of a clade C DNA vaccine ADVAX e/g
+ ADVAX p/n-t (ADVAX) administered intramuscularly to HIV uninfected,
healthy volunteers

NCT00111605

2005

Phase

Interventions

Official title

2005 NCT00249106
(comp.
2003)

Trial ID

Date
reg’d
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R

NYR

R

NLR

T

NLR

NLR

NLR

R

NLR

Status

T

P

T

P

T

P

P

T

P

P

Preventive/
therapeutic
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J. Bailey

NCT00545987

2007

Evaluation of local and systemic reactogenicity following serial administration of
ADVAX, a clade C DNA vaccine, ADVAX e/g + ADVAX p/n-t, by Ichor TriGrid™
in vivo electroporation to HIV uninfected, healthy volunteers

Official title

NCT00083330

NCT00091416

NCT00095576

NCT00102089

NCT00108654

NCT00119873

2004

2004

2004

2005

2005

2005

MRK Ad5 HIV-1 gag

V520

Safety of and immune response to an experimental HIV vaccine
(VRC-HIVADV014-00-VP) in HIV uninfected adults

A phase I clinical trial to evaluate the safety and immunogenicity of a booster
dose of a recombinant multiclade HIV-1 adenoviral vector vaccine,
VRC-HIVADV014-00-VP, in uninfected subjects who were previously immunised
with VRC-HIVDNA016-00-VP in VRC 00

VRC-HIVADV014-00-VP

VRC-HIVADV014-00-VP

A phase I clinical trial to evaluate the safety and immunogenicity of a booster dose VRC-HIVADV014-00-VP
of a recombinant multiclade HIV-1 adenoviral vector vaccine,
VRC-HIVADV014-00-VP
VRC-HIVADV014-00-VP, in uninfected subjects who were previously immunised
booster
with VRC-HIVDNA009-00-VP in VRC 004

Investigation of V520 in an HIV vaccine proof-of-concept study

Safety of and immune response to an HIV-1 vaccine boost
VRC-HIVADV014-00-VP
(VRC-HIVADV014-00-VP) in HIV uninfected adults who participated in HVTN 052

A phase I clinical trial to evaluate the safety and immunogenicity of a recombinant VRC-HIVADV014-00-VP
multiclade HIV-1 adenoviral vector vaccine, VRC-HIVADV014-00-VP, in
uninfected adult volunteers

Effectiveness of and immune response to HIV vaccination followed by treatment
interruption in HIV infected patients

ADVAX-EP

Interventions

I

I

I

II

I

I

II

I

Phase

NLR

NLR

C

T

NLR

NLR

NLR

R

Status

P

P

P

P

P

P

T

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

NCT00080106

2004

Recombinant microbial vaccines Adenovirus

Trial ID

Date
reg’d
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NCT00183261

NCT00350623

NCT00413725

NCT00479999

NCT00486408

2005

2006

2006

2007

2007

A phase IB open-label clinical trial to expand the characterisation of the
immune responses to the Merck adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
in healthy, HIV-1 uninfected adult participants

VRC 012: A phase I clinical trial of the safety and immunogenicity of an HIV-1
adenoviral vector serotype 35 dose escalation as a single agent and prime–boost
schedules with an HIV-1 adenoviral vector serotype 5 vaccine in uninfected adults

A multicentre double-blind randomised placebo-controlled phase IIB test-ofconcept study to evaluate the safety and efficacy of a three-dose regimen of the
clade B-based Merck adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in HIV-1
uninfected adults in South Africa

Investigation of V520 in a HIV vaccine dose refinement study

A randomised phase II study of therapeutic immunisation and treatment
interruption among subjects who began potent antiretroviral therapy within 30
days of diagnosis of acute or recent HIV infection

Official title

A phase I randomised, placebo-controlled, double-blind dose-escalation trial to
evaluate the safety and immunogenicity of tgAAC09, a gag-PR-RT AAV HIV
vaccine

NCT00000767

NCT00051922

NCT00187044

NCT00189930

1999

2003

2005

2005

A single-blind, randomised, controlled, phase II study to evaluate immunogenicity
and safety of two doses of the MVA-nef HIV vaccine in HIV-1 infected patients
with CD4 > 250/µl

Evaluation of the safety of a polyvalent vaccinia virus-HIV-1 envelope
recombinant vaccine (PolyEnv1) in healthy adults

Development of a new HIV vaccine

A multicentre, randomised, placebo-controlled, double-blind trial to evaluate the
safety and immunogenicity of a recombinant vaccinia-HIV-1 IIIB env/gag/pol
vaccine (TBC-3B)

Recombinant microbial vaccines Vaccinia

2007 NCT00482027
(comp.
2003)

Recombinant microbial vaccines Adeno-associated virus

Trial ID

Date
reg’d

Table 1: continued

MVA-nef
MVA-BN

PolyEnv1

PolyEnv1

TBC-3B vaccine

tgAAC09

MRKAd5 HIV-1 gag/pol/nef

VRC-HIVADV027-00-VP
VRC-HIVADV038-00-VP

MRKAd5 HIV-1 gag/pol/nef

V520

MRKAd5 HIV-1 gag/pol/nef

Interventions

II

I

I

I

I

I

I

II

II

II

Phase

NLR

NLR

NLR

C

C

S

R

S

T

NLR

Status

T

P

P

P

P

P

P

P

P

T

Preventive/
therapeutic

398
J. Bailey

NCT00252148

NCT00376090

NCT00386633

NCT00390078

2005

2006

2006

2006

Single-blind, randomised, controlled, phase I/II vaccination study on safety and
immunogenicity of a recombinant MVA-HIV polytope vaccine (MVA-mBN32) in
HIV-1 infected patients with CD4 counts > 250/µl

A phase I, open, sequential vaccination study on safety and tolerability of two
different doses of a recombinant MVA HIV polytope vaccine (MVA-mBN32) in
HIV-negative 18–50 year old healthy volunteers

A phase I double-blind, randomised, dose-escalating, placebo-controlled study of
safety and immunogenicity of WRAIR/NIH live recombinant MVA-CMDR
(HIV-1 CM235 env/ CM240 gag/pol) administered by IM or intradermal route in
HIV uninfected adults

A randomised, placebo-controlled, dose-escalating, double-blinded phase I study to
evaluate the safety and immunogenicity of a Modified Vaccinia Ankara (MVA)
expressing HIV-1 clade C env/gag-pol and nef-tat fusion genes (ADMVA) vaccine
administered intramuscularly to HIV uninfected, healthy volunteers

Official title

NCT00001136

2000

A study of the effectiveness of an HIV vaccine (ALVAC vCP205) to boost immune
functions in HIV-negative volunteers who have already received an HIV vaccine

Safety and effectiveness of anti-HIV vaccines in HIV-negative adults

ALVAC-HIV MN120TMG
(vCP205)

ALVAC(2)120(B,MN)GNP
(vCP1452)
gp160 MN/LAI-2
ALVAC(1)120(B,MN)GNP
(vCP1433)
ALVAC-HIV MN120TMG
(vCP205)

MVA-mBN32
MVA-BN

MVA-mBN32

MVA-CMDR

ADMVA

Interventions

I

I

I/II

I

I

I

Phase

NLR

C

R

NLR

R

R

Status

P

P

T

P

P

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

NCT00000904

1999

Recombinant microbial vaccines Canarypox

Trial ID

Date
reg’d
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NCT00006291

NCT00007423

NCT00011011

NCT00013572

NCT00013663

NCT00026624

NCT00027261

NCT00056797

NCT00076817

NCT00098163

NCT00219362

2000

2000

2001

2001

2001

2001

2001

2003

2004

2004

2005

2003

NCT00063778

ALVAC(2)120(B,MN)GNP
(vCP1452)

Interventions

A phase II, randomised, placebo-controlled study to evaluate the immunogenicity
and the safety of 2 schedules of an homologous prime–boost with the ALVAC-HIV
vCP1452 in chronically HIV infected patients

Safety of an HIV vaccine (AVX101) in HIV uninfected volunteers in the USA
and South Africa

AVX101

vCP1452

ALVAC-HIV vCP1521

ALVAC-HIV (vCP205)

Safety and effectiveness of administering an HIV vaccine in the groin versus the
arm

A phase I study to evaluate the safety and immunogenicity of ALVAC-HIV
vCP1521 in infants born to HIV-1 infected women in Uganda

ALVAC HIV vaccine
(vCP1452)

Therapeutic HIV vaccine and interleukin-2 to increase the immune system’s
response to HIV

ALVAC(2)120(B,MN)GNP
(vCP1452)

ALVAC(2)120(B,MN)GNP
(vCP1452)

Safety/immunogenicity of immunisations of ALVAC-DC-SC vs ALVAC-SC

Safety and immune response study of high-dose canarypox ALVAC-HIV vaccine
in healthy, HIV uninfected adults

ALVAC(2)120(B,MN)GNP
(vCP1452)

ALVAC-HIV MN120TMG
(vCP205)

ALVAC(2)120(B,MN)GNP
(vCP1452)

Immune therapies and anti-HIV therapy withdrawal in controlling viral load

HIV candidate vaccine, ALVAC-HIV-1, administration in HIV-negative adults

Vaccine (ALVAC-HIV vCP1452) use and intermittent withdrawal of anti-HIV
drugs in patients with HIV

Safety and effectiveness of the vaccine ALVAC-HIV vCP205 in HIV-negative adult ALVAC-HIV MN120TMG
volunteers in Uganda
(vCP205)

Safety and effectiveness of adding either an HIV vaccine, interleukin-2, or both to
a patient’s anti-HIV drug combination

Official title

Recombinant microbial vaccines Venezuelan Equine Encephalitis alphavirus

Trial ID

Date
reg’d
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I

II

I

I

II

I

I

II

I

I/II

I

II

Phase

C

NLR

NLR

NLR

C

NLR

NLR

C

NLR

C

C

C

Status

P

T

P

P

T

P

T

T

P

T

P

T

Preventive/
therapeutic

400
J. Bailey

NCT00097838

2004

A phase I, dose escalation, safety, and immunogenicity trial of an alphavirus
replicon HIV-1 subtype C gag vaccine (AVX101) in healthy HIV-1 uninfected
adult participants

Official title

NCT00062530

Development of an oral prime–boost AIDS vaccine to elicit broadly neutralising
antibodies against HIV-1

NCT00107549

NCT00301184

2005

2006

A phase I clinical trial to evaluate the safety and immunogenicity of pGA2/JS7
DNA vaccine and recombinant Modified Vaccinia Ankara/HIV62 vaccine in
healthy, HIV-1 uninfected adult participants

A phase I, open-label study to evaluate the safety and tolerability of recombinant
HIV-1 vaccines in HIV-1 infected young adults with control of HIV-1 replication
and on stable HAART

Safety of and immune response to two HIV vaccine formulations (rMVA-HIV and
rFPV-HIV) alone or in combination in HIV uninfected adults

pGA2/JS7 DNA
Modified Vaccinia
Ankara/HIV62

rMVA-HIV (env/gag
[TBC-M358] + tat/rev/nefRT [TBC-M335)]) rFPV-HIV
(env/gag [TBC-F357] + tat/
rev/nef-RT [TBC-F349])

rMVA-HIV (rMVA-HIV
env/gag + rMVA-HIV
tat/rev/nef-RT) FPV-HIV
(rFPV-HIV env/gag +
rFPV-HIV tat/rev/nef-RT)

SCBaL/M9 (oral recombinant
Salmonella typhi HIV-1
gp120 vaccine)

HIV-1 subtype C gag
vaccine, AVX101

Interventions

I

I

I

I

I

Phase

R

S

NLR

NYR

NLR

Status

P

T

P

P

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

NCT00083603

2004

Recombinant microbial vaccines Multiple

2003

Recombinant microbial vaccines Salmonella typhi

Trial ID

Date
reg’d
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Trial ID

NCT00056758

NCT00058734

NCT00402142

NCT00407836

NCT00510497

2003

2003

2006

2006

2007

Phase I/II evaluation of therapeutic immunisation with autologous dendritic cells
pulsed with autologous, inactivated HIV-1 infected, apoptotic cells

Phase II study of efficacy, tolerability and safety of CD4-specific T-cell vaccine in
HIV infection

Phase II study of autologous myeloid dendritic cells as a ‘cellular adjuvant’ for a
therapeutic HIV-1 vaccine in early stage HIV-1+ patients (DCV-2)

Therapeutic vaccination followed by treatment interruption in HIV infected
patients

HIV vaccine designed for HIV infected adults taking anti-HIV drugs

NCT00073216

2003

Safety of and immune response to a combination HIV vaccine regimen in HIV
uninfected adults

Safety of and immune response to polyvalent HIV-1 vaccine in HIV uninfected
adults

1999

NCT00001090

A multicentre, randomised, placebo-controlled, double-blinded, phase I trial to
evaluate the safety and immunogenicity of live recombinant canarypox ALVACHIV vCP205 combined with GM-CSF in healthy, HIV-1 uninfected volunteers
AMENDMENT 4/30/99: To study the safety of following 4 ALVAC immunisations
with a nucleic acid gag/pol HIV-1 immunogen (APL-400-047, Wyeth-Lederle)

Multi-component vaccines Canarypox/DNA

NCT00061243

2003

Interventions

I

I

Clade B gag DNA/PLG and
env DNA/PLG microparticles
Clade B recombinant,
oligomeric gp140/MF59
adjuvant

APL 400-047
ALVAC-HIV MN120TMG
(vCP205)

I

I/II

II

I/II

I

I

II

Phase

HIV-1 DNA vaccine with
protein vaccine boost
(multiple Env antigens in
both parts)

Autologous HIV-1 ApB DC
vaccine

T-cell vaccination

Dendritic cell vaccine

Dendritic cells pulsed with
HIV antigens [peptides]

Autologous dendritic cell
HIV vaccination

Pilot study of autologous T-cell transplantation with vaccine driven expansion of
Therapeutic autologous
anti-tumour effectors after cytoreductive therapy in metastatic paediatric sarcomas dendritic cells

Official title

Multi-component vaccines DNA/protein

NCT00019266

2001

Autologous cells

Date
reg’d
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C

NLR

NLR

R

R

R

C

C

C

Status

P

P

P

T

T

T

T

T

T

Preventive/
therapeutic

402
J. Bailey

Trial ID

Official title

NCT00333424

NCT00476749

2006

2007

A randomised, placebo-controlled, double-blind, phase I clinical trial to evaluate
the safety and immunogenicity of a candidate prophylactic pHIS-HIV-AE DNA
prime and rFPV-HIV-AE boost HIV vaccination strategy

A randomised, placebo-controlled, double-blind, phase I clinical trial to evaluate
the safety and immunogenicity of a candidate prophylactic pHIS-HIV-AE DNA
prime and rFPV-HIV-AE boost HIV vaccination strategy

Evaluation of the safety of and immune response to an HIV vaccine in healthy
adults

NCT00123968

2005

A phase I/II clinical trial to evaluate the safety and immunogenicity of a
multiclade HIV-1 DNA plasmid vaccine, VRC-HIVDNA016-00-VP, boosted by a
multiclade HIV-1 recombinant adenovirus-5 vector vaccine, VRC-HIVADV01400-VP, in HIV uninfected adult volunteers in East Africa

VRC-HIVDNA016-00-VP
VRC-HIVADV014-00-VP

VRC 008: A phase I clinical trial of a prime–boost HIV-1 vaccination schedule:
VRC-HIVDNA016-00-VP
Multiclade DNA vaccine, VRC-HIVDNA016-00-VP, followed by multiclade
VRC-HIVADV014-00
adenoviral vector vaccine, VRC-HIVADV014-00-VP, in uninfected adult volunteers

pHIS-HIV-AE DNA prime
rFPV-HIV-AE booster
vaccine

Prime: (pHIS-HIV-AE)
encoding the HIV-1 AE
antigens, modified Gag, Pol,
Tat/Rev and Env
Boost: non-replicating,
recombinant fowlpox virus
(rFPV-HIV-AE) encoding the
HIV-1 AE antigens, modified
Gag, Pol, Tat/Rev and Env

HIV DNA plasmid vaccine
plus recombinant fowlpox
vector

Interventions

I/II

I

I

I

I/II

Phase

R

NLR

R

NYR

C

Status

P

P

P

P

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

NCT00109629

2005

Multi-component vaccines Adenovirus/DNA

NCT00051454

2003

Multi-component vaccines Fowlpox/DNA

Date
reg’d
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Trial ID

NCT00124007

NCT00125970

NCT00270218

NCT00270465

NCT00321061

NCT00384787

NCT00415649

NCT00472719

Date
reg’d

2005

2005

2005

2005

2006

2006

2006

2007

Table 1: continued

VRC-HIVDNA016-00-VP
VRC-HIVADV014-00-VP
(‘rAd5 vaccine’)

VRC-HIVDNA016-00-VP
VRC-HIVADV014-00-VP

VRC-HIVADV014-00-VP
VRC-HIVDNA009-00-VP

VRC-HIVDNA016-00-VP
VRC-HIVADV014-00-VP

VRC-HIVADV014-00-VP
VRC-HIVDNA016-00-VP

Interventions

VRC-HIVDNA016-00-VP
VRC-HIVADV014-00-VP

A phase IB clinical trial to evaluate the safety and immunogenicity of
VRC-HIVADV027-00-VP
recombinant adenoviral serotype 35 (rAd35) and serotype 5 (rAd5) HIV-1 vaccines VRC-HIVADV038-00-VP
when given in heterologous prime–boost regimens or as a boost to a recombinant VRC-HIVDNA044-00-VP
DNA vaccine in healthy, HIV-1 uninfected adult participants with pre-existing
immunity to adenovirus serotype 5 infection

A phase II, randomised, placebo-controlled, double-blind trial to evaluate the
safety and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine followed
by recombinant, multiclade HIV-1 adenoviral vector vaccine in healthy adult
volunteers at risk for HIV infection

A phase IB clinical trial to compare the safety, tolerability, and immunogenicity of VRC-HIVDNA009-00-VP
an HIV-1 adenoviral vector boost administered intramuscularly, intradermally,
VRC-HIVADV014-00-VP
or subcutaneously after an HIV-1 DNA plasmid vaccine prime administered
intramuscularly to healthy adenovirus type 5 seropositive HIV-1 uninfected adults

VRC 011: A phase I clinical trial of intramuscular, subcutaneous and intradermal
administration of an HIV-1 multiclade DNA vaccine, VRC-HIVDNA016-00-VP,
and an HIV-1 multiclade adenoviral vector vaccine, VRC-HIVADV014-00-VP, in
uninfected adult volunteers

VRC101: A phase I clinical trial to evaluate the safety and immunogenicity of a
prime–boost HIV-1 vaccination schedule of a 6-plasmid multiclade HIV-1 DNA
vaccine, VRC-HIVDNA016-00-VP, followed by a recombinant multiclade
adenoviral vector HIV vaccine

A phase I clinical trial to evaluate immune response kinetics and safety of two
different primes, adenoviral vector vaccine (VRC-HIVADV014-00-VP) and DNA
vaccine (VRC-HIVDNA009-00-VP), each followed by adenoviral vector boost in
healthy, HIV-1 uninfected adults

A phase II clinical trial to evaluate the safety and immunogenicity of a multiclade
HIV-1 DNA plasmid vaccine, VRC-HIVDNA016-00-VP, followed by a multiclade
recombinant adenoviral vector HIV-1 vaccine boost, VRC-HIVADV014-00-VP, in
HIV-1 uninfected adult participants

Safety of and immune response to an adenoviral HIV vaccine (VRC-HIVADV01400-VP) with or without a plasmid HIV vaccine (VRC-HIVDNA016-00-VP) in HIV
uninfected adults

Official title

I

II

I

I

I

I

II

I

Phase

R

NYR

R

NLR

NLR

NLR

NLR

NLR

Status

P

P

P

P

T

P

P

P

Preventive/
therapeutic

404
J. Bailey

NCT00498056

2007

A phase IIB test-of-concept, randomised, double-blind, placebo-controlled,
international clinical trial to evaluate the efficacy, safety, and immunogenicity of
a multiclade HIV-1 DNA plasmid vaccine, VRC-HIVDNA016-00-VP, followed by
a multiclade recombinant adenoviral vector vaccine, VRC-HIVADV014-00-VP, in
HIV uninfected persons

Official title

NCT00490074

2007

A phase I/II trial to compare the immunogenicity and safety of 3 DNA-C prime
followed by 1 NYVAC-C boost to 2 DNA-C prime followed by 2 NYVAC-C boost

A phase I clinical trial to evaluate the safety and immunogenicity of DNA vaccine
EP-1233 and recombinant MVA-HIV polytope vaccine MVA-mBN32, separately
and in a combined prime–boost regimen, when given to healthy, vaccinia-naïve,
HIV-1 uninfected adults

NCT00000631

NCT00000683

1999

1999

A phase I multicentre, randomised, double-blind trial to evaluate the safety and
immunogenicity of recombinant vaccinia virus expressing the envelope
glycoproteins of human immunodeficiency virus

A phase I randomised trial to evaluate the safety and immunogenicity of
vaccinia-HIV envelope recombinant vaccine (HIVAC-1e) in combination with
soluble recombinant envelope vaccine (VaxSyn)

Phase I safety and immunogenicity trial of vaccinia-HIV envelope recombinant
vaccine (HIVAC-1e) in combination with soluble recombinant envelope vaccine
(gp160; VaxSyn)

HIVAC-1e
gp160 vaccine (MicroGeneSys)

HIVAC-1e
gp160 vaccine (MicroGeneSys)

HIVAC-1e
gp160 vaccine (MicroGeneSys)

DNA-C
NYVAC-C

EP-1233
MVA-mBN32

VRC-HIVDNA016-00-VP
VRC-HIVADV014-00-VP

Interventions

I

I

I

I/II

I

II

Phase

C

C

C

R

R

NYR

Status

P

P

P

P

P

P

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

NCT00000630

1999

Multi-component vaccines Vaccinia/recombinant protein

NCT00428337

2007

Multi-component vaccines Vaccinia/DNA

Trial ID

Date
reg’d
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NCT00000746

NCT00000866

NCT00001026

NCT00002261

1999

1999

1999

1999

A comparative phase I clinical study of HIVAC-1e and smallpox (vaccinia)
vaccines in previously (vaccinia) vaccinated and unvaccinated volunteers

A phase I, multicentre, randomised trial to evaluate the safety and
immunogenicity of a recombinant vaccinia-HIV envelope vaccine (HIVAC-1e) in
combination with a panel of subunit recombinant HIV envelope vaccines in
vaccinia-naïve individuals

A multicentre, randomised, placebo-controlled, double-blind trial to evaluate the
safety and immunogenicity of the Therion recombinant vaccinia-HIV-1 IIIB
ENV/GAG/POL vaccine (TCB-3B) and MN rgp120/HIV-1 in alum

A phase I, multicentre, randomised trial to evaluate the safety and
immunogenicity of a recombinant vaccinia-HIV envelope vaccine (HIVAC-1e) in
combination with a panel of subunit recombinant HIV envelope vaccines

Official title

NCT00332930

An extension study to protocol VIR-NCHR-01 to assess the antiretrovirological
properties of a therapeutic HIV vaccine candidate based on recombinant fowlpox
virus (rFPV) (ITV extension study)

NCT00000813

NCT00000847

NCT00000871

1999

1999

1999

A phase II safety and immunogenicity trial of live recombinant canarypox
ALVAC-HIV vCP205 with or without HIV-1 SF-2 rgp120 in HIV-1 uninfected
adult volunteers

A phase I safety and immunogenicity trial of live recombinant canarypox ALVACHIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 uninfected adult volunteers

A phase I safety and immunogenicity trial of live recombinant canarypox-gp160
MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 uninfected adult volunteers

Multi-component vaccines Canarypox/recombinant protein

2006

Multi-component vaccines Fowlpox/recombinant protein

Trial ID

Date
reg’d
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MN rgp120/HIV-1 and
GNE8 rgp120/HIV-1
MN rgp120/HIV-1 and
A244 rgp120/HIV-1
ALVAC-HIV MN120TMG
(vCP205)
rgp120/HIV-1 SF-2

ALVAC-HIV MN120TMG
(vCP205)
rgp120/HIV-1 SF-2

ALVAC-HIV gp160MN
(vCP125)
rgp120/HIV-1 SF-2

Recombinant fowlpoxvirus
(rFPV) expressing HIV
gag-pol antigens
HIV gag-pol antigens and
interferon-gamma (IFN-γ)

HIVAC-1e
gp160 vaccine (MicroGeneSys)

gp160 vaccine
(Immuno-AG)
rgp120/HIV-1IIIB
rgp120/HIV-1MN
rgp120/HIV-1 SF-2
HIVAC-1e

MN rgp120/HIV-1
TBC-3B vaccine

rgp120/HIV-1 SF-2
Env 2-3
HIVAC-1e

Interventions

II

I

I

I/II

I

I

—

I

Phase

NLR

C

C

C

C

C

C

C

Status

P

P

P

T

P

P

P

P

Preventive/
therapeutic

406
J. Bailey

NCT00000879

NCT00000884

NCT00000946

NCT00001055

NCT00001072

NCT00001076

1999

1999

1999

1999

1999

1999

A phase I safety and immunogenicity trial of live recombinant canarypox
ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 uninfected volunteers to
evaluate accelerated vaccine schedules

A phase I safety and immunogenicity trial of live recombinant canarypox ALVACHIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 uninfected adult volunteers

A phase I safety and immunogenicity trial of live recombinant canarypox
ALVAC-HIV (vCP205) in HIV-1 uninfected adult volunteers

A study to test the safety of three experimental HIV vaccines

A randomised phase I safety and immunogenicity trial of live recombinant
canarypox ALVAC-HIV vCP205 delivered by alternate mucosal routes in HIV-1
uninfected adult volunteers

A study of the effects of giving two anti-HIV vaccines to babies of HIV-positive
mothers

Official title

ALVAC-HIV MN120TMG
(vCP205)
ALVAC-RG rabies
glycoprotein (vCP65)
rgp120/HIV-1 SF-2

ALVAC-HIV MN120TMGNP
(vCP300)
rgp120/HIV-1 SF-2

ALVAC-HIV MN120TMG
(vCP205)
rgp120/HIV-1 SF-2

HIV p24/MF59 vaccine
ALVAC-HIV MN120TMG
(vCP205)
rgp120/HIV-1 SF-2

MN rgp120/HIV-1 and
GNE8 rgp120/HIV-1
ALVAC-HIV MN120TMG
(vCP205)

ALVAC(2)120(B,MN)GNP
(vCP1452)
MN rgp120/HIV-1 and
GNE8 rgp120/HIV-1
ALVAC-HIV MN120TMG
(vCP205)

Interventions

I

I

I

I

I

I

Phase

C

C

C

NLR

NLR

NLR

Status

P

P

P

P

P

P/T

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

Trial ID

Date
reg’d
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NCT00011037

2001

ALVAC-HIV vCP1452 alone and combined with MN rgp120

Safety and immune response study of the vaccine ALVAC vCP1452 alone or in
combination with AIDSVAX B/B

NCT00000868

A study to evaluate the safety and effectiveness of HIV-1 LAI gp120 (an HIV
vaccine) given with or without HIV-1 MN rgp120 (another HIV vaccine) to
HIV-negative volunteers

NCT00005758

NCT00006495

2000

2000

Immune responses in HIV-positive patients receiving an anti-HIV drug
combination when given the HIV vaccines Remune and vCP1452

Effectiveness of giving an HIV vaccine (Remune) to HIV-positive patients
receiving an anti-HIV drug combination

Multi-component vaccines Canarypox/inactivated virus

1999

Multi-component vaccines Salmonella typhi/recombinant protein

NCT00337181

Extended evaluation of the virologic, immunologic, and clinical course of
volunteers who become HIV-1 infected during participation in a phase III vaccine
trial of ALVAC-HIV and AIDSVAX B/E

NCT00007332

2000

A study of the safety and effectiveness of an HIV vaccine for HIV-positive
patients receiving anti-HIV drugs for at least 2 years

2006

NCT00006509

2000

Interventions

ALVAC(2)120(B,MN)GNP
(vCP1452)
HIV-1 immunogen (Remune)

ALVAC(2)120(B,MN)GNP
(vCP1452)
HIV-1 immunogen

Salmonella typhi CVD
908-HIV-1 LAI gp120
(VVG 203)
rgp120/HIV-1MN

ALVAC-HIV (vCP1521)
AIDSVAX B/E: bivalent
HIV gp120

ALVAC-HIV vCP1521
AIDSVAX gp120 B/E

ALVAC(2)120(B,MN)GNP
(vCP1452)
MN rgp120/HIV-1

ALVAC(2)120(B,MN)GNP
(vCP1452)
MN rgp120/HIV-1 and
GNE8 rgp120/HIV-1

ALVAC(2)120(B,MN)GNP
(vCP1452)
gp160 MN/LAI-2

A phase I, dose-ranging trial of the Pasteur Merieux Connaught (PMC) oligomeric gp160 MN/LAI-2
HIV-1 gp160MN/LAI-2 vaccine alone or primed with live recombinant
ALVAC-HIV MN120TMG
ALVAC-HIV (vCP205) in HIV seronegative adults
(vCP205)

A phase III trial of Aventis Pasteur live recombinant ALVAC-HIV (vCP1521)
priming with VaxGen gp120 B/E (AIDSVAX B/E) boosting in HIV uninfected
Thai adults

NCT00004579

1999

Official title

2005 NCT00223080
(comp.
2003)

Trial ID

Date
reg’d
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I

III

I

—

III

II

II

I

I

Phase

C

C

C

R

NLR

NLR

C

NLR

C

Status

T

T

P

P

P

P

P

T

P

Preventive/
therapeutic
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NCT00212888

2005

A pilot study to determine the impact of therapeutic HIV vaccination followed by
a scheduled interruption of antiretroviral therapy on HIV-specific immune
function and virologic rebound in patients with prolonged viral suppression

Official title

NCT00196651

2005

Randomised study on HIV immune and virological responses following the
administration of IL-2 either alone or combined to ALVAC-HIV 1433 and HIV
lipopeptides (LIPO-6T) in patients treated early with HAART during primary
infection. ANRS 095 PRIMOVAC

A study of LIPO-5 and ALVAC-HIV (vCP1452) as possible HIV vaccines

NCT00002428

NCT00434512

A dose-ranging study to compare the safety and immunogenicity of a candidate
HIV vaccine 732461, adjuvanted or not, administered according to a 0, 1, 6
months schedule to healthy adult HIV seronegative volunteers

A phase I/II safety and immunogenicity trial of UBI microparticulate monovalent
(HIV-1 MN) branched peptide vaccine in HIV-1 seronegative human subjects

HIV vaccine 732461

HIV-1 peptide vaccine,
microparticulate monovalent
rgp120/HIV-1MN monovalent
octameric V3 peptide vaccine

LIPO-6T
ALVAC HIV 1433
IL-2

ALVAC-HIV (vCP1452)
LIPO-5

Remune
ALVAC

Interventions

I/II

I/II

II

I/II

I/II

Phase

NLR

C

T

NLR

R

Status

P

P

T

P

T

Preventive/
therapeutic

Data were considered, up to and including 11 November 2007. Records of AIDS vaccine clinical trials retrieved from http://www.clinicaltrials.gov. A search was performed by
using the operators ‘AIDS OR HIV’ in the Disease or Condition field and ‘vaccine’ in the Experimental Treatment field, and it included all trials that were no longer recruiting
patients. This search produced 197 results, detailing clinical trials involving 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into
account, meaning strain MN recombinant gp120 was considered a separate vaccine from strain SF-2 recombinant gp120). The date the trial was registered is not necessarily the
date the trial commenced; where both dates are known, these are given, with the earliest being 1999 when the database was initiated, though trials may have begun prior to this
date (comp. = [trial] completed). For trial status, C = Completed, T = Terminated, S = Suspended, NLR = No Longer Recruiting, NYR = Not Yet Recruiting, R = Recruiting.
The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which
vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among
other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees.

2007

Unknown

1999

Multi-component vaccines Virus-like particles/peptide

NCT00076063

2004

Multi-component vaccines Canarypox/peptide or lipopeptide

Trial ID

Date
reg’d
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human trials (43). The ability of recombinant gp160
protein to confer protection was also shown in
chimpanzees (44, 45), as it was in other studies
where a variety of vaccines were also protective to
chimpanzees, such as whole inactivated virus,
recombinant vaccinia-gp160, the recombinant proteins p18 gag, p27 nef and p23 vif, and peptide
immunogens (46, 47). This protection in chimpanzees extended to challenge with HIV-infected
lymphocytes, as well as with free virus (48).
Recombinant gp160 protein was also protective in
chimpanzees when boosted with V3 peptides (49,
50).
Also, one of the two aforementioned AIDSVAX
vaccines, produced by VaxGen, was the first candidate HIV vaccine to complete a Phase III trial (43),
closely followed by the other. AIDSVAX B/B (comprising gp120 envelope proteins from two clade B
strains of HIV, MN and GNE8) failed to protect
more than 5000 trial participants (mainly gay men)
at high risk of HIV infection (51), and AIDSVAX B/E
(comprising gp120 from strains MN and A244 [clade
E]) failed to provide protection against HIV infection
for over 2500 users of injected drugs in Thailand
(52), despite repeated booster immunisations
throughout the study. These failures occurred
despite the fact that AIDSVAX achieved the greatest
immune response of any vaccine of this type (35).
The dearth of active clinical trials of this kind of
vaccine, coupled with high-profile failures, has
prompted some to consider that the concept of the
induction of neutralising antibodies as an HIV vaccine strategy has ‘run aground’ (53). Evidence suggests this was recognised by many scientists some
time ago, there having been a distinct re-focusing of
efforts to develop an effective vaccine toward other
approaches, as well as an admission that recombinant proteins could be used only as part of a
‘prime–boost’ vaccine regimen.

Peptide/lipopeptide vaccines
Peptide/lipopeptide vaccines constitute 14 (7%) of
the 197 registered clinical trials, and involve nine
different vaccines. They contain small fragments of
HIV proteins, rather than the complete molecules,
which makes them simpler and cheaper. These
fragments often contain the most immunogenic
parts of the HIV proteins, targeting an immune
response to dominant T-cell epitopes and neutralising determinants (54), and several peptides from
different strains of HIV can be contained in one vaccine. More recently, they have been combined with
lipid molecules to form ‘lipopeptides’, in order to
increase their immunogenicity (55).
In common with recombinant protein vaccines,
most trials of peptides/lipopeptides were registered,
and therefore took place, in and around 1999. Just
four trials have been registered since 2004. All but

J. Bailey

one (13/14) of the trials are Phase I trials; the
exception is a Phase II trial of the LIPO-5 vaccine,
which is listed as no longer recruiting participants.
As may be expected due to the lack of trial progression, and in common with trials of recombinant protein vaccines, success has not been reported (2, 35,
56, 57), despite, for example, reports of potent and
long-lasting B-cell and T-cell responses to lipopeptide immunisation in chimpanzees (58).
No chimpanzee trials of this type of vaccine were
listed in the NHPVT database.

Virus-like particles
Virus-like particles (VLPs, also known as ‘pseudovirions’) can be generated by the in vitro or in vivo (such
as in transfected cells) production of HIV-1 viral proteins, which can spontaneously assemble into particles. Only two registered trials were found in
ClinicalTrials.gov, which were both Phase I trials
registered in 1999. One of these (‘HIV-1 Pseudovirion’ vaccine) was terminated prior to completion.
Young et al. (31), however, report that the other
vaccine (HIV p17/p24:Ty-VLP) has also been tested
in a Phase II trial (59). In contrast to results
obtained in mice, vaccinated individuals had low
levels of both humoral and cell-mediated immunity.
This vaccine also showed no significant effect on
disease progression in HIV-infected volunteers in a
long-term follow-up study (60). Young et al. (31)
also cite another Phase I trial with VLPp24 vaccine,
which failed to augment immunity to HIV in
infected patients (61).
No chimpanzee trials of this type of vaccine were
listed in the NHPVT database.

DNA vaccines
Twenty-five (13%) of the 197 registered trials
involved 14 different DNA vaccines, whereby plasmids containing HIV genes are used to induce
immunity to the virus when injected intramuscularly. Cells exposed to such plasmids ‘ingest’ the
DNA, which is then transcribed and translated by
the host cells to produce the cognate viral proteins.
When ‘proof of concept’ was initially demonstrated
by injecting DNA into the muscles of mice (62), it
was subsequently shown that proteins produced in
this manner could induce significant humoral and
cellular immune responses (63–65).
The NHPVT database contained three records of
DNA vaccine trials in chimpanzees (NHP .226,
NHP .202 and NHP .71), all of which demonstrated
immunogenicity. One trial provided protection
from HIV infection to an uninfected chimpanzee,
and one vaccine induced an indefinite decrease in
viral load, when used as a therapeutic vaccine for
infected chimpanzees. The other trial was also ther-
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apeutic in nature, and also decreased viral load,
though this effect was transient.
Twenty-five (13%) of the 197 registered trials
examined 14 DNA vaccines. All but three of these
25 trials were Phase I trials, with the remaining
three being Phase I/II trials. Just eight of the 25 trials had been completed at the time of writing, and
one trial of a gag DNA vaccine registered in 2005
has already been terminated.
Many researchers thought that DNA vaccination
would revolutionise vaccine development for many
diseases, not just for HIV. The first human trial
involved HIV-1 strain MN env gp160 and rev genes
(66), and although marginal increases in anti-gp160
cytotoxic T-lymphocyte (CTL) activity were observed
in a small number of volunteers, there was no
change in CD4+ T-cell count or plasma viral load.
Subsequent trials have continued to fall short: for
example, plasmids encoding nef, tat or env genes
have been only slightly immunogenic (67, 68), and
just three of the trials are anything other than Phase
I trials (i.e. Phase I/II). This disappointment is
reflected in the opinions of authors of several recent
reviews on the topic: “Although immunisation with
DNA plasmids that contain HIV inserts has elicited
substantial cellular responses in mice and nonhuman primates, these products have been poorly
immunogenic in humans.” (5); “Plasmid DNA constructs have proved to be effective immunogens in
mice for eliciting cellular immune responses and for
priming antibody responses. It is now clear, however,
that DNA vaccines are less immunogenic in nonhuman primates than they are in mice, and even less
immunogenic in humans than in non-human primates.” (69); and “Although DNA vaccines are
immunogenic in mice and monkeys (including
neonates), current vaccines are poorly immunogenic
when administered alone to people.” (70).
There is ample supporting evidence for such opinions. DNA vaccination has been shown in numerous
studies to produce strong virus-specific immune
responses, and to be protective against HIV infection in chimpanzees (71–74).
The initial failures with ‘native’ DNA vaccines
have led to efforts to augment vaccine DNA expression by using co-expressed cytokines (notably interleukin [IL]-12 and IL-15; 5) and adjuvants (55, 75,
76; see Table 1), by improving DNA delivery techniques (77, 78), by using the DNA vaccines in a
combination ‘prime–boost’ approach, and by using
a variety of genetic techniques, such as promoter
modification and codon optimisation (79, 80).

Recombinant microbial vaccines (RMVs)
RMV trials constitute 21% (or 41/197) of all registered clinical trials, and involve the use of microorganisms that have been genetically engineered to
include HIV genes. Almost all of the vectors are
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viral, though the bacterium, Salmonella typhi, has
also been used. The principle involves using the
microorganism to carry the HIV genes into the cells
of the vaccinated individual, where those genes are
expressed and rendered subject to host immune
responses via presentation on the host cell-surface
in association with Major Histocompatibility
Complex (MHC) Class I molecules.
Thirty-seven of the 41 trials have been of individual vaccines, and four involved more than one
type of vaccine in this class. Collectively, 24 different vaccines have been tested in these trials, with
27 Phase I, 11 Phase II, two Phase I/II and one
Phase III trials initiated. RMVs are a relatively new
approach to the development of an HIV vaccine,
reflected in the fact that just ten clinical trials have
reached a conclusion, and that, excluding the
canarypox class of vaccines, all but one of the trials
were registered in or after 2003. It seems, however,
that the primary emphasis of HIV trials has moved
toward this approach (5), given the recent high profile failures of recombinant-protein vaccines in
Phase III trials, for example (81–83).
Of the concluded trials, seven of the ten were
completed, two were terminated, and one was suspended.

Adenovirus
Twelve trials involving five adenovirus vaccines
(based on the ‘common cold’ virus) are registered,
constituting 29% of all the trials involving RMVs.
This approach has received much attention, for a
number of reasons: adenoviruses induce mucosal
immunity, which should help prevent HIV infection
at genital/rectal sites; they infect dendritic cells, leading to the efficient presentation of viral antigens; and
they elicit long-term humoral and cell-mediated
immunity (84). They have also given successful
results, including protection from HIV infection, in
studies in several non-human species, including nonhuman primates, for example macaques (85) and
chimpanzees (86–88). A combination approach,
involving recombinant adenovirus-gp160 and gp120
proteins, was also successful in chimpanzees, protecting them from even high-dose challenges of HIV after
only a few immunisations (89–91).
Clinical work in this area is fairly advanced, with
half of these trials being in Phase II, though two of
them have been terminated. These terminated trials involved Merck’s V520 vaccine, which comprises
a recombinant Ad5 adenovirus containing the HIV
gag, pol and nef genes. Despite being widely considered by experts as “one of the most promising to be
tested on people so far” (92), trials of the vaccine
were terminated in September 2007, when an
interim analysis prior to the planned completion in
2008 concluded that the vaccine simply wasn’t
working. It had failed to protect thousands of

Trial ID

Title/description (reference)

NHP .152.1 Prevention of HIV-1 infection in chimpanzees by
NHP .152.2 gp120 V3 domain-specific monoclonal antibody (15)

NHP .84

1992

1999

Immune response of chimpanzees after immunisation Whole inactivated HIV-1 IIIB
with the inactivated whole immunodeficiency virus
(HIV-1), three different adjuvants and challenge (37)

NHP .242

NHP .247

1988

1989

rgp120

gp120

Human immunodeficiency virus type I challenge of
chimpanzees immunised with recombinant envelope
glycoprotein gp120 (148)

Challenge of chimpanzees (Pan troglodytes)
immunised with human immunodeficiency virus
envelope glycoprotein gp120 (149)

Recombinant protein

NHP .204

Whole inactivated virus

1993

CB1 anti-V3

CD4 Immunoadhesin
(CD4-IgG)
CHO-SIVgp120

Postexposure immuno-prophylaxis of primary
mAb B4
isolates by an antibody to HIV receptor complex (147)

Prevention of HIV-1 IIIB infection in chimpanzees
by CD4 immunoadhesin (23)

NHP .156

1991

N/A

Antibody-mediated in vitro neutralisation of human
immunodeficiency virus type I abolishes infectivity
for chimpanzees (20)

NHP .241
NHP .243

1990

HIVIG

Intervention(s)

Failure of human immunodeficiency virus (HIV)
immune globulin to protect chimpanzees against
experimental challenge with HIV (146)

NHP .361

1988

Passive (e.g. antibody-mediated)

Date

Monoclonal antibody directed
against HIV receptor complex









Vaccine purified from HIVinfected cell-lines
Strain IIIB

Vaccine from CHO cell line

Hybrid mouse–human antibody to
the V3 loop of HIV-1 strain IIIB





Soluble CD4 analogue, which
competes for CD4 binding to the
HIV gp120 envelope glycoprotein

Challenge inocula mixed with
neutralising antibody prior to
infection

/



Passive antibody, intravenous







—

—

—

—

—

Outcome
Outcome Protective/
Immuno- Protective/
immunotheragenic?
genic? therapeutic?
peutic?
Notes

Table 2: Chimpanzee AIDS vaccine trials listed in the nonhuman primate HIV/SIV vaccine trials database
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NHP .267

NHP .362

NHP .193

NHP .198

NHP .21

1990

1991

1995

1996

2001

NHP .202

1997

rgp160

gp160

gp120

Intervention(s)

HIV-1 W6.1D gp120

HIV-1.MN rgp120

DNA vaccination as anti-human immunodeficiency
virus immunotherapy in infected chimpanzees (151)

pCMN160 HIV-1.MN env-rev

Protection of chimpanzees from high-dose
DNA vaccine encoding env, rev
heterologous HIV-1 challenge by DNA vaccination (71) and gag/pol

Protection from secondary human immunodeficiency
virus type 1 infection in chimpanzees suggests the
importance of antigenic boosting and a possible role
for cytotoxic T cells (150)

Protection of MN-rgp120-immunised chimpanzees
from heterologous infection with a primary isolate of
human immunodeficiency virus type 1 (41)

Resistance of chimpanzees immunised with
rgp120
recombinant gp120SF2 to challenge by HIV-1SF2 (42)

Immunisation of chimpanzees with the HIV-1
glycoprotein gp160 induces long-lasting T-cell
memory (44)

Protection of chimpanzees from infection by HIV-1
after vaccination with recombinant glycoprotein
gp120 but not gp160 (40)

Title/description (reference)















/

/



—









Outcome
Outcome Protective/
Immunoimmuno- Protective/
theragenic?
genic? therapeutic?
peutic?

DNA plasmid vaccine expressing
env and rev

Recombinant gp120 protein from
strain W6.1D

Strain SF2, expressed in CHO
cells

Vaccine produced in CHO cells

Notes

Date were considered, up to and including 11 November 2007. Records of AIDS vaccine trials in chimpanzees were retrieved from the Nonhuman Primate HIV/SIV Vaccine
Trials Database (http://www.hiv.lanl.gov/content/vaccine/home.html). This search produced results of 24 vaccine trials (accounting for duplicates). Column five indicates
whether the vaccine was immunogenic in chimpanzees (indicated by a check/cross for yes/no, or a dash where not explicitly measured); column six indicates whether the vaccine
was effective in preventing HIV infection or controlling it (indicated by a check/cross for yes/no, or a dash where not explicitly measured). Interventions are shown in plain,
underlined, or bold text, to indicate which vaccines were subsequently tested in clinical trials, given the caveat that the frequent poor quality of vaccine information requires this
to be an educated guess: Plain text = no evidence found for subsequent testing in humans; Underlined text = similar but not identical to vaccine tested in humans (e.g. same
plasmid containing same HIV gene among other genes; different adjuvant; etc.); Bold text = identical vaccine tested in humans.

NHP .226

1997

DNA vaccines

Trial ID

Date
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NHP .71

2000

Therapeutic immunisation of HIV-infected
chimpanzees by using HIV-1 plasmid antigens and
interleukin-12 expressing plasmids (72)

Title/description (reference)

NHP .244

NHP .318

1989

2000

Multi-envelope HIV vaccine safety and
immunogenicity in small animals and chimpanzees
(154)

Cell-mediated immune proliferative responses to
HIV-1 of chimpanzees vaccinated with different
vaccinia recombinant viruses (153)

Effect of immunisation with a vaccinia-HIV
recombinant on HIV infection in chimpanzees (152)

NHP .225

Challenge of chimpanzees immunised with a
recombinant canarypox-HIV-1 virus (155)

1991

NHP .159

Immunisation of chimpanzees confers protection
against challenge with human immunodeficiency
virus (46)

Multi-component vaccines

1997

Recombinant microbial vaccines Canarypox

NHP .249

1987

Recombinant microbial vaccines Vaccinia

Trial ID

Date

Table 2: continued

Whole inactivated virus
Purified recombinant proteins
Synthetic peptides

ALVAC-HIV-1 vCP250

Recombinant vaccinia virus-env

VVF

VV25

VV160

v-env5

pCGag/Pol

pCMN160 HIV-1.MN env-rev

Intervention(s)







/









—





/

Recombinant virus expresses gp120
gag and protease gene products

Vaccinia virus expresses multiple
envelope proteins

Recombinant vaccinia-gp160 virus
(VV160)
Recombinant vaccinia-p25 virus
(VV25)
Recombinant vaccinia-F/3´ orf
virus (VVF)

Recombinant vaccinia-env virus

DNA constructs expressing MN
strain Env and Rev proteins
Decrease in viral loads observed,
though transient

Outcome
Outcome Protective/
Immuno- Protective/
immunotheragenic?
genic? therapeutic?
peutic?
Notes
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NHP .167

NHP .141

NHP .465

1998

1998

2005

Replicating rather than non-replicating adenovirus–
human immunodeficiency virus recombinant
vaccines are better at eliciting potent cellular
immunity and priming high-titre antibodies (91)

Vaccine protection against a heterologous,
non-syncytium-inducing, primary human
immunodeficiency virus (90)

Fine specificity of anti-V3 antibodies induced in
chimpanzees by HIV candidate vaccines (156)

Title/description (reference)

—



Prime: Ad5 and Ad7
adenoviruses, both replication
competent and deficient
Boost: oligomeric gp140 delta V2









Prime: rec. adenovirus-gp160
(MN)
Boost: gp120 protein (SF2)

(ii) gp160 plus V3 peptide boost

(i) vCP125/gp160 combination

Intervention(s)

Sequential priming immunisations
with different serotypes of
adenovirus env-rev recombinants,
and boosting with oligomeric
gp140 delta V2 (strain SF162)

(i) Recombinant canarypox
ALVAC (expressing gp160 MN),
plus gp160 (MN/LAI strain)
(ii) gp160 MN/LAI strain plus
synthetic V3 peptide

Outcome
Outcome Protective/
Immuno- Protective/
immunotheragenic?
genic? therapeutic?
peutic?
Notes

Date were considered, up to and including 11 November 2007. Records of AIDS vaccine trials in chimpanzees were retrieved from the Nonhuman Primate HIV/SIV Vaccine
Trials Database (http://www.hiv.lanl.gov/content/vaccine/home.html). This search produced results of 24 vaccine trials (accounting for duplicates). Column five indicates
whether the vaccine was immunogenic in chimpanzees (indicated by a check/cross for yes/no, or a dash where not explicitly measured); column six indicates whether the vaccine
was effective in preventing HIV infection or controlling it (indicated by a check/cross for yes/no, or a dash where not explicitly measured). Interventions are shown in plain,
underlined, or bold text, to indicate which vaccines were subsequently tested in clinical trials, given the caveat that the frequent poor quality of vaccine information requires this
to be an educated guess: Plain text = no evidence found for subsequent testing in humans; Underlined text = similar but not identical to vaccine tested in humans (e.g. same
plasmid containing same HIV gene among other genes; different adjuvant; etc.); Bold text = identical vaccine tested in humans.

Trial ID

Date
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Of 40 single-intervention recombinant microbial
vaccine trials, eight, involving seven vaccinia-virus
based interventions, were identified, though just
one trial has been completed. All but two are Phase
I trials, with one trial at Phase I/II and another at
Phase II.
Three trials involving recombinant vaccinia vaccines in chimpanzees were identified in the NHPVT
database. Although all the vaccines were immunogenic, the two trials that took place in the 1980s did
not show protection from HIV infection. The other
trial took place more recently in 2000, but only
assessed immunogenicity.
Modified Vaccinia Ankara virus (MVA) forms the
basis of many recombinant vaccinia approaches to an
HIV vaccine, because of its high degree of attenuation
and consequent good safety profile. Initial results in
human trials, however, have been disappointing, with
cell-mediated immunity being elicited in only a small
minority of individuals (96), despite promising results
in macaques (5). Human trials that include MVA vaccines as part of a prime–boost strategy have also been
disappointing (6).

gether around a third of the total (13/41, or 32%), five
of which have progressed to Phase II; the remainder
are Phase I trials. These trials involved four different
vaccines, all based upon the ALVAC vector developed
by Sanofi-Pasteur (based on an attenuated strain of
canarypox). In principle, these vectors are highly fitfor-purpose: they replicate only in the cytoplasm of
infected cells (minimising the risk of integration with
the host genome and any ensuing problems); replication is restricted; and they are sufficiently safe and
well tolerated in humans (97, 98). Further, they can
accommodate large gene insertions (99), and they can
stimulate both humoral and cell-mediated immune
responses of long duration in humans (100–102).
An early Phase I/II trial ended in disappointment,
however, when a gp160 vaccine (ALVAC-HIV)
failed to enhance both humoral and cell-mediated
immune responses (103). Looking at the register of
clinical trials (Table 1), further failures with other
ALVAC trials appear to have followed. Focus seems
to have shifted to other approaches, signalled by the
low number of trials registered in recent years
(compared to 1999–2001, for example). This is true,
not just for trials solely involving canarypox, but
also for the many trials of AIDS vaccines involving
recombinant canarypox in combination with other
approaches such as the use of DNA and recombinant proteins. In addition, it has been reported that
five different canarypox vaccines have been tested
in around 11,500 volunteers (5). Though well tolerated, these vaccines did not induce durable immune
responses, and were immunogenic in fewer than
20% of the subjects (104).
Canarypox vaccines have also been tested in children, with similarly disappointing results. For
example, the vCP205 and vCP1452 vaccines were
given to very young infants of HIV+ mothers; again,
they were well tolerated, but produced humoral and
cell-mediated immune responses either not at all, or
of a very low magnitude (105). Comparison with
chimpanzee vaccinations is difficult, as just one
such trial is listed in the NHPVT database, involving three animals. In this instance, the vCP250 vaccine was immunogenic, and protected one of the
two experimental animals from cell-associated viral
challenge. It did not, however, protect this chimpanzee against subsequent infection with cell-free
HIV (Table 2).
As mentioned previously, many trials have used
canarypox in combination with other vaccine candidates — though this has not resulted in an improvement in efficacy. For example, vCP1452 has been
administered with an AIDSVAX B/B boost to
infants, but enthusiasm for further trials was limited due to ‘modest immunogenicity’ (70).

Canarypox

Others

Vectors based on the canarypox virus constitute the
biggest proportion of trials involving RMVs — alto-

Two clinical trials involved the use of Venezuelan
Equine Encephalitis alphavirus (VEE) as a vector.

volunteers from HIV infection, and also to reduce
HIV levels in people already infected. Disturbingly,
more HIV infections were present in those who had
been given the vaccine, as compared to those given
the placebo (24 versus 21, respectively), with those
who had been in the trial longer and who had
received more injections faring even worse, with 19
cases of HIV infection after vaccination versus just
11 after placebo treatment (93, 94).
As this was the first viral-recombinant vaccine to
reach this stage of clinical trials, and the first to
examine cell-mediated immunity alone in humans
(53), some believe that it raises questions about
whether the use of RMVs can be successful at all,
particularly as vaccines based on adenovirus have
appeared to be the most immunogenic in terms of
the percentage of human responders and the level
and duration of T-cell responses (95).
Adeno-associated virus
Just one trial was identified involving recombinant
adeno-associated virus (AAV), which was registered
in 2007, although it commenced in 2003. This
Phase I trial has been completed, and evaluated an
AAV containing clade C gag, pro, and rt HIV
sequences.
Vaccinia
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Both Phase I trials, they assessed the vaccine
AVX101, which contains the HIV gag gene as an
immunogen. Another trial, registered in 2003 but
not yet recruiting participants, proposes to evaluate
a vaccine based on recombinant Salmonella typhi
containing the HIV gp120 gene.
Three clinical trials, all registered relatively
recently (2004–2006), involved more than one type
of RMV. Two of the three trials investigated combinations of vaccinia-based (MVA) and fowlpox-based
vaccine pairs, each containing the env/gag and
tat/rev/nef HIV genes. The status of the earlier of
the two trials is ‘no longer recruiting,’ though the
details state that all vaccinations were discontinued
in November 2006, and the other trial has been suspended. The third trial will assess a ‘prime–boost’
intervention involving an initial DNA plasmid vaccine ‘prime’, followed by a Modified Vaccinia
Ankara (MVA) ‘boost’ (this approach is described in
more detail later in this review).

Autologous cells
Dendritic cells are one of the first ports-of-call for
the virus upon infection. They are locally infected
at the entry site of the virus, before proceeding to
the lymph nodes where they infect CD4+ T-cells —
the principal target of the virus, the attrition of
which leads to AIDS. Consequently, dendritic cells
are central to the induction of the immune response
to HIV infection, though their response is known to
decline with time (106–109).
With this in mind, six trials have been registered
that involve two types of autologous-cell approach
to therapeutic HIV vaccination: five with dendritic
cells, and the other with T-cells. The former strategy involves harvesting a patient’s own dendritic
cells and loading them in vitro with HIV peptide
antigens or inactivated autologous virus. The latter
T-cell based vaccine is prepared from autologous Tcells, which have proliferated following exposure to
recombinant CD4. The cells are then introduced
back into the patient, in the hope that they can better activate immune responses that can control the
infection. Early results in humans are considered
promising, at least against the same viral strain
used to produce the cell-based vaccine (110), though
this must be interpreted with caution, as any efficacious vaccine must elicit immune responses
against diverse strains of HIV.
No chimpanzee trials of this vaccine type were
listed in the NHPVT database, though the immunogenicity in chimpanzees of dendritic cells pulsed
with test antigens has been reported in the scientific literature, with somewhat equivocal results
(111, 112), and a T-cell vaccine for hepatitis C has
been tested in chimpanzees, which elicited immunity against heterologous hepatitis C virus (HCV;
113).
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Multi-component vaccines and prime–boost
strategies
Due to negative results in many trials involving single vaccines of all types, much focus has shifted
toward the development of multi-component vaccines, in so-called ‘prime–boost’ strategies. This
type of intervention aims to enhance the immune
response to a particular antigen, and to induce both
the humoral and cell-mediated arms of the immune
response by administering it in successive, but
slightly different, ways — especially when using
just one route/vaccine type has not proved sufficiently immunogenic. The rationale is to ‘prime’ the
immune system with the first antigen (for example,
a DNA vaccine or recombinant adenovirus or
poxvirus), and then to ‘boost’ the immune response
to it by using, for example, another RMV or protein.
Fifty clinical trials were identified in this category
(Figure 5), with the most prevalent combinations
being canarypox–protein (15 trials), adenovirus–DNA
(11 trials) and vaccinia–protein (7 trials). Given the
relatively recent nature of this type of approach, the
majority of the trials are Phase I trials (31/50), with
just seven Phase II and two Phase III trials. One of
the Phase II trials, involving a canarypox–lipopeptide
vaccine (ALVAC HIV-1433 and LIPO-6T), was terminated, and a recent publication revealed that HIVspecific CD4+ T-cell responses did not change in
immunised patients relative to controls, that the vaccination had only a transient effect on interferongamma-producing CD8 responses, and that the viral
rebound after treatment interruption was similar in
immunised patients and controls (114). The Phase III
trial, involving a canarypox–inactivated virus vaccine
(vCP1452 and Remune), was registered in 2000 and
has been completed (without success), and the other
trial, involving a canarypox–protein vaccine combination (vCP1521 and AIDSVAX gp120 B/E), commenced in 2003 and is no longer recruiting.
Despite this Phase II termination and the lack of
reported success surrounding the Phase II trials,
much hope is held in some quarters for this strategy, largely based on pre-clinical studies in monkeys, where prime–boost vaccines are often more
potent than either vaccine alone (55). The NHPVT
database lists four chimpanzee trials of multi-component vaccines, one of which tested two different
vaccine combinations. All five combinations were
immunogenic. One of the trials (NHP .465), involving an adenovirus prime and an oligomeric gp140
boost, did not assess protection from infection, but
all the other vaccines demonstrated protection,
except one, which comprised a vCP125/gp160 combination (trial NHP .167). In addition to those studies registered with the NHP database, Girard et al.
(47) reported the protection of chimpanzees from
HIV infection following immunisation with “a variety of HIV-1 immunogens — followed by rgp160
and V3 peptides”, including combinations of enve-
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lope antigens. This all contrasts with findings in
humans, however, where “observations in early
phase clinical trials in humans have not been promising”, due to adverse reactions and lack of diversity
in the immune response (115).
Naturally, not all the vaccines tested in chimpanzees have provided protection against HIV challenge. One of the vaccine combinations tested by
Girard et al. (47), for example, described a combination strategy involving recombinant gp160–
canarypox and recombinant gp160 protein, that
failed, although the low dose of the vaccine was postulated as a factor.

Summary and Discussion
To date, 85 candidate AIDS vaccines have been
tested in 197 clinical trials, comprising several main
types — from inactivated virus vaccines through
DNA plasmids to recombinant proteins and viruses.
Just 12% of these trials have reached Phase II, only
seven (3.5%) have reached Phase III, and altogether, 18 trials were prematurely terminated.
None has been successful.
Early optimism has transformed into a realisation that we are decades away from even a partially
effective vaccine in humans. The monumental
financial and human resources allocated to vaccine
development have resulted in dozens of safe and
effective vaccines only for chimpanzees and monkeys with laboratory-induced infections. Hope that
the use of NHPs will lead to the successful development of a vaccine for humans is tempered by the
recent, high-profile failures of the AIDSVAX and
V520 (Merck) candidates in extensive and late-stage
clinical trials. Notably, the latter increased the risk
of HIV infection compared to the placebo — and it
is not alone in this respect: previously, gp120-based
vaccines increased the risk that vaccinated people
would develop an infection or progress to AIDS
post-infection (116).
Furthermore, the limited critical appraisal to date
of the favoured SIV/chimeric SIV–Human Immunodeficiency Virus (SIV/SHIV)-macaque model, has
been unfavourable (35, 53, 56, 117–121), stimulating
a desire for models of greater relevance. While some
scientists associated with chimpanzee research advocate a resumption of their use, such use must be
objectively and independently evaluated.

Poor performance of the chimpanzee model
in the development of AIDS vaccines
This analysis expands on previous data that underlined the poor performance of chimpanzees as models in HIV/AIDS research, evidenced by a large
number of negative opinions and comments toward
it and by the significant withdrawal of NIH funding
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for it. The evidence provided, based on a comparison of human and chimpanzee responses to AIDS
vaccines, gives further argument against a return
to chimpanzee-use in this field.
Contrary to claims that chimpanzees play a “critical role in the testing of potential [HIV] vaccines”
and that they “are still important for testing vaccines aimed at preventing HIV-1 infection or reducing the virus load in infected individuals”(14), this
review shows that neither claim has any scientific
foundation. Many vaccines of many types have been
tested in chimpanzees prior to clinical trials, and
their correlation to, and predictive nature for, the
human response is demonstrably poor. Chimpanzees have been protected from HIV infection passively via the transfer of antibodies (both pre- and
post-exposure), which prompted the (now highly
unlikely) suggestion that cell-mediated immunity is
not necessary. Passive protection has also been
induced by a soluble CD4 analogue. Neither
approach has been successful in humans. Attenuated vaccines have provided protection in chimpanzees, but have not been tested clinically due to
safety concerns. Inactivated-virus vaccines have
disappointed clinically, and while results were similarly negative in chimpanzees, these results were of
little relevance and did not prevent inactivatedvirus vaccines from progressing to clinical trials.
Negative results with recombinant protein vaccines
in chimpanzees (Table 2) also did not stop these
vaccines progressing to further testing and clinical
trials (122).
While RMVs have been disappointing in humans,
including the Phase III AIDSVAX trials, many
(excluding a couple of early efforts) provided protection from HIV infection in chimpanzees. Clinical trial
success with peptide and lipopeptide vaccines has not
been reported, despite prior evidence of potent and
persistent cell-mediated immune responses in chimpanzees. Both preventive and therapeutic DNA vaccination have been successful in chimpanzees.
Optimism for success in humans was high, but poor
immunogenicity has led to recent disparaging comments. Recombinant adenovirus vaccines have
elicited protection from HIV infection in chimpanzees, both alone and in combination with recombinant HIV proteins. However, the situation in
humans may be grave, with possibly “the most promising [vaccine] tested on people so far”, in the form of
Merck’s V520 vaccine, not only ending in the termination of its Phase IIb trial, but increasing the risk of
HIV infection for its recipients.
Due to the diminished use of chimpanzees in
pre-clinical testing for reasons discussed above,
some types of vaccines have not been widely tested
in chimpanzees. Immunogenicity has been demonstrated in chimpanzees with vaccinia-based vaccines, however — which is true in only a small
minority of humans in clinical trials so far.
Similarly, canarypox vaccines have induced pro-
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tection from cell-associated (but not cell-free)
virus challenge in chimpanzees, but several vectors have been immunogenic in a small proportion
of clinical-trial volunteers, including children,
even as part of prime–boost regimens — and then
only poorly so. Some prime–boost vaccines, involving a variety of immunogens, have proven positive
in chimpanzees, again in contrast to humans, in
which the results have been disappointing, replete
with adverse reactions and lack of diversity in the
immune response.

Problems with the chimpanzee model:
Reasons for its lack of relevance
Researchers continue to rely on results largely from
macaques infected with SIV or SHIV (an SIV/HIV
hybrid), despite important differences between SIVinfected macaques and HIV-infected humans (53,
117). Significant disparities exist in virulence,
pathology, genetics, protein function, infection and
host response (118). Two recent reviews stated
that, “efficacy of HIV-1 based vaccines cannot be
directly evaluated in the SIV model” (119) and that,
“this has not proven a practical animal model for
studying vaccines” (35), the latter citing significant
supporting evidence (56, 121, 122). A 2007 review
stated, “When it comes to testing HIV vaccines,
only humans will do” (53); another cited, “the persistent view held by many that there is no predictive animal model for HIV infection in humans”
(123), and another that, “No animal models faithfully reproduce... HIV-1 infection and disease in
humans, and the studies of experimental vaccines
in animal models... have yielded disparate results”
(124).
Yet the rhesus macaque became the model of
choice following the discovery in 1987 that SIV
caused an AIDS-like disease in these animals (125).
It replaced the chimpanzee, widely used in AIDS
research for several years previously but which had
“had problems from the get-go” (125) — vis-à-vis
practicality (the significant costs of using and maintaining chimpanzees, including user’s fees of
$50,000+ per animal), statistical significance (few
animals could be used in each experiment, giving
unreliable results), and species differences (HIV
infection rarely progresses to AIDS-like illness in
chimpanzees) “undermining the model’s reliability” (125). The latter problem of scientific unreliability is, from a human perspective, most worrying.
If years of chimpanzee use in HIV/AIDS research
have not led to tangible progress and improvements
clinically, then they represent a waste of limited
resources and have done little to alleviate human
suffering, as there is still no AIDS vaccine and none
is imminent. A brief summary of the known differences between human and chimpanzee HIV infection and ensuing pathology may explain why.
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Chimpanzees have higher baseline levels of CD8+
T-cells and a higher ratio of CD8+/CD4+ T-cells,
and their percentage of beta-chemokine-positive
CD8+ T-cells and natural killer (NK) cells is significantly higher than in uninfected humans.
Chimpanzees do not typically produce increased
numbers of these cells following HIV infection,
unlike humans (126). As these are the cells that
attempt to control infection, and the latter are the
cells infected by HIV-1 and subsequently destroyed
by the virus, this is critical. Unlike in humans, it is
difficult to routinely isolate HIV from the plasma
and sera of infected chimpanzees (127), and chimpanzee CD4+ cell numbers do not drop dramatically
over the course of HIV infection, with remarkably
few exceptions. Instead, detectable plasma HIV
decreases and eventually becomes undetectable
(117). With perhaps only one exception, HIV infection of chimpanzees does not result in a significant
decline in CD4+ T-cell levels, immunodeficiency
and AIDS-like illness, as in humans. The exception
was Jerom (‘Chimpanzee C499’), who was infected
with three different isolates of HIV-1 over ten years
and suffered a progressive decline in CD4+ T-cells
and developed AIDS-like symptoms, caused by a
quasispecies of HIV that had mutated to become
more pathogenic (128). Notably, Jerom’s blood,
though it caused a similar decline in CD4+ T-cells
in other chimpanzees transfused with it, did not
cause them to develop a similar disease (129).
These differences, difficulties, and the lack of a
vaccine led many scientists to conclude that chimpanzees should have no place in the quest for an
AIDS vaccine. In 1994, the Handbook of Laboratory
Animal Science called primate models of AIDS
“unsuccessful” (130). The NIH AIDS Research
Program Evaluation Task Force cited the “limited
utility of the chimpanzee model” and recommended
“redirecting monies currently expended in the less
relevant chimpanzee model” (131). The latter was
put into practice: AIDS-related chimpanzee studies
fell from almost 30 studies in 1998 to four in 2005.
Thomas Insel M.D., former director of the Yerkes
Regional Primate Center, noted that 15 years of
work in chimpanzees has produced little data relevant to humans, stating “I can’t tell you what it is
that those [chimpanzee] studies have given us that
has really made a difference in the way we approach
people with this disease [HIV/AIDS]” (132); and a
review article in 2000 opined “Defending the usefulness of the chimpanzee as a model for HIV
research has not only become a difficult task, but
also a controversial one” (133).
These realisations came too late. At least 198
chimpanzees were deliberately infected with HIV
prior to 1997 (134), and around 1,300 chimpanzees
are currently in US laboratories, due in large part
to over-breeding for AIDS research in anticipation
of their use in this area, and despite a breeding
moratorium being in place for the past decade.
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Ethical issues associated with chimpanzee use
Ethics must be considered alongside scientific relevance, because of the cost of chimpanzee use, and
because chimpanzees are a ‘special case’, testified to
by public and scientific opinion, and policies and
laws in the US and throughout the world. The passage of the CHIMP (Chimpanzee Health Improvement, Maintenance and Protection) Act in the USA
in 2000, as well as the fact that many countries ban
or restrict the use of great apes, acknowledges a different moral status for chimpanzees. Both scientists and the public acknowledge that chimpanzees
have advanced cognitive abilities, and social and
emotional needs. They are capable of reasoned
thought, abstraction, generalisation and symbolic
representation; have a concept of self; exhibit a
broad range of emotions; experience mental as well
as physical pain; and can be taught to communicate
in human languages such as American Sign Language, and demonstrate complex nonverbal communication patterns among themselves (135–142). In
captivity, they show a range of behavioural abnormalities and measurable signs of distress (psychopathology; 143, 144). The widely-respected
researcher and advocate for chimpanzee welfare,
Jane Goodall, stated in a letter to Science that, “It
is their humanlike behaviours that most fascinate
people: their tool-using and making abilities, the
close supportive bonds among family members…
and their complex social interactions — the cooperation, the altruism, and the expression of emotions
like joy and sadness” (145).
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panzee trials of inactivated-virus and DNA vaccines, concluded “it proved difficult to examine the
effect of these vaccines, due to the general lack of
clinical progression to immunodeficiency in this
animal model and the prohibitive cost of these
experiments” (7).
Some twenty years after chimpanzees were the
mainstay of AIDS vaccine testing, an efficacious
vaccine for human use remains unavailable and not
imminent. The use of chimpanzees has largely been
abandoned for scientific and cost–benefit reasons.
As millions of humans continue to become infected
or die each year, the continued use of chimpanzees
in AIDS research is scientifically unwise and ethically unjustifiable.

Received 03.04.08; received in final form 27.06.08;
accepted for publication 28.06.08.

Acknowledgements
Jarrod Bailey was the sole author of this manuscript and was responsible for its conception,
research and preparation. The work herein has not
been presented anywhere else prior to this publication. Sincere gratitude is expressed to the New
England Anti-Vivisection Society for funding the
project, and to Theodora Capaldo and all the others
who offered their time and expertise in reviewing
the manuscript during its preparation. There are no
conflicts of interest.

Conclusions

References

The evidence presented in this study includes:

1.

— substantial differences between chimpanzee and
human responses to HIV infection and the
course of the disease;

2.

— expert opinion;

3.

— past failures as a vaccine model;
— progression of vaccines to clinical trials despite
negative results in chimpanzees;

4.

— increasing knowledge of chimpanzees’ cognitive
and emotional capacities; and
— increased ethical issues surrounding chimpanzee research.

5.

From this evidence, it is concluded that chimpanzees have no justifiable role in AIDS vaccine
research and testing. Advocating the resumption of
their use defies the burden of scientific evidence of
repeated failures involving their use. If chimpanzees were not reliable, predictive and fit for purpose from 1990 to 2008, what justification is there
for a resumption of their use? A 2006 review of
AIDS vaccine testing, when referring to chim-

6.

7.
8.

Derdeyn, C.A. & Silvestri, G. (2005). Viral and host
factors in the pathogenesis of HIV infection.
Current Opinion in Immunology 17, 366–373.
Douek, D.C., Kwong, P.D. & Nabel, G.J. (2006).
The rational design of an AIDS vaccine. Cell 124,
677–681.
Girard, M., Mastro, T.D. & Koff, W.C. (2003).
Human Immunodeficiency Virus. In Vaccines, 4th
edn (ed. S.A. Plotkin & W.A. Orenstein), pp. 1219–
1258. Philadelphia, PA, USA: Saunders.
Girard, M.P. & Koff, W.C. (2008). Human Immunodeficiency Virus Vaccines. In Vaccines, 5th edn (ed.
S.A. Plotkin, W.A. Orenstein & P.A. Offit), pp.
1213–1251. Philadelphia, PA, USA: Saunders.
Duerr, A., Wasserheit, J.N. & Corey, L. (2006). HIV
vaccines: new frontiers in vaccine development.
Clinical Infectious Diseases 434, 500–511.
Girard, M.P., Osmanov, S.K. & Kieny, M.P. (2006).
A review of vaccine research and development: the
human immunodeficiency virus HIV. Vaccine 24,
4062–4081.
Puls, R.L. & Emery, S. (2006). Therapeutic vaccination against HIV: current progress and future
possibilities. Clinical Science 110, 59–71.
National Institute of Allergy and Infectious Diseases
(NIAID) (2005). Clinical Trials of HIV Vaccines.
NIAID Fact Sheet. Available at: http://www.niaid.

422

9.

10.

11.

12.

13.
14.
15.

16.

17.

18.

19.

20.

21.

J. Bailey

nih.gov/factsheets/clinrsch.htm (Accessed 03.04.08).
Kelleher, A.D., Roggensack, M., Jaramillo, A.B.,
Smith, D.E., Walker, A., Gow, I., McMurchie, M.,
Harris, J., Patou, G., & Cooper, D.A. (1998). Safety
and immunogenicity of a candidate therapeutic
vaccine, p24 virus-like particle, combined with
zidovudine, in asymptomatic subjects. AIDS 122,
175–182.
Kahn, J.O., Cherng, D.W., Mayer, K., Murray, H.,
Lagakos, S.; for the 806 Investigator Team (2000).
Evaluation of HIV-1 immunogen, an immunologic
modifier, administered to patients infected with
HIV having 300 to 549 × 106/L CD4 cell counts.
Journal of the American Medical Association 284,
2193–2202.
Bailey, J. (2005). Non-human primates in medical
research and drug development: a critical review.
Biogenic Amines 19, 235–255. Available at: http://
www.curedisease.net/pdfs/reportbiogenic.pdf
(Accessed 03.04.08).
AIDS Vaccine Advocacy Coalition (AVAC) (2004).
AIDS Vaccine Trials — Getting the Global House in
Order. Available at: http://www.iavi.org/viewpage.
cfm?aid=22 (Accessed 03.04.08).
Day, M. (2007). AIDS expert doubts vaccine will be
found in near future. British Medical Journal 334,
1133.
VandeBerg, J.L. & Zola, S.M. (2005). A unique biomedical resource at risk. Nature, London 437, 30–32.
Emini, E.A., Schleif, W.A., Nunberg, J.H., Conley,
A.J., Eda, Y., Tokiyoshi, S., Putney, S.D., Matsushita, S., Cobb, K.E., Jett, C.M., Eichberg, J.W. &
Murthy, K.K. (1992). Prevention of HIV-1 infection
in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature, London 355, 728–730.
Conley, A.J., Kessler, J.A. II, Boots, L.J., McKenna,
P.M., Schleif, W.A., Emini, E.A., Mark, G.E. III,
Katinger, H., Cobb, E.K., Lunceford, S.M., Rouse,
S.R. & Murthy, K.K. (1996). The consequence of
passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal
antibody before challenge of chimpanzees with a
primary virus isolate. Journal of Virology 70,
6751–6758.
Murthy, K.K., Cobb, E.K., Rouse, S.R., Lunceford,
S.M., Johnson, D.E. & Galvan, A.R. (1996). Correlates of protective immunity against HIV-1 infection in immunized chimpanzees. Immunology
Letters 51, 121–124.
Cho, M.W., Lee, M.K., Chen, C.H., Matthews, T. &
Martin, M.A. (2000). Identification of gp120
regions targeted by a highly potent neutralizing
antiserum elicited in a chimpanzee inoculated with
a primary human immunodeficiency virus type 1
isolate. Journal of Virology 74, 9749–9754.
Girard, M.P., Osmanov, S.K. & Kieny, M.P. (2006).
A review of vaccine research and development: the
human immunodeficiency virus (HIV). Vaccine 24,
4062–4081.
Emini, E.A., Nara, P.L., Schleif, W.A., Lewis, J.A.,
Davide, J.P., Lee, D.R., Kessler, J., Conley, S., Matsushita, S., Putney, S.D., Gerety, R.J. & Eichberg,
J.W. (1990). Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. Journal of Virology
64, 3674–3678.
Prince, A.M., Reesink, H., Pascual, D., Horowitz, B.,
Hewlett, I., Murthy, K.K., Cobb, K.E. & Eichberg,
J.W. (1991). Prevention of HIV infection by passive

22.

23.

24.

25.

26.

27.

28.

29.
30.
31.
32.

33.
34.

immunization with HIV immunoglobulin. AIDS Research & Human Retroviruses 7, 971–973.
Stiehm, E.R., Fletcher, C.V., Mofenson, L.M., Palumbo, P.E., Kang, M., Fenton, T., Sapan, C.V.,
Meyer, W.A., Shearer, W.T., Hawkins, E., Fowler,
M.G., Bouquin, P., Purdue, L., Sloand, E.M., Nemo,
G.J., Wara, D., Bryson, Y.J., Starr, S.E., Petru, A. &
Burchett, S. (2000). Use of human immunodeficiency
virus (HIV) human hyperimmune immunoglobulin
in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). Journal of Infectious
Diseases 181, 548–554.
Ward, R.H., Capon, D.J., Jett, C.M., Murthy, K.K.,
Mordenti, J., Lucas, C., Frie, S.W., Prince, A.M.,
Green, J.D. & Eichberg, J.W. (1991). Prevention of
HIV-1 IIIB infection in chimpanzees by CD4
immunoadhesin. Nature, London 352, 434–436.
Meng, T.C., Fischl, M.A., Cheeseman, S.H., Spector,
S.A., Resnick, L., Boota, A., Petrakis, T., Wright, B.
& Richman, D.D. (1995). Combination therapy with
recombinant human soluble CD4-immunoglobulin G
and zidovudine in patients with HIV infection: a
phase I study. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 8, 152–160.
Clerici, M., Yarchoan, R., Blatt, S., Hendrix, C.W.,
Ammann, A.J., Broder, S. & Shearer, G.M. (1993).
Effect of a recombinant CD4-IgG on in vitro T helper
cell function: data from a phase I/II study of patients
with AIDS. Infectious Diseases 168, 1012–1016.
Armbruster, C., Stiegler, G.M., Vcelar, B.A., Jäger,
W., Michael, N.L., Vetter, N. & Katinger, H.W.
(2002). A phase I trial with two human monoclonal
antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS
16, 227–233.
Armbruster, C., Stiegler, G.M., Vcelar, B.A., Jäger,
W., Köller, U., Jilch, R., Ammann, C.G., Pruenster,
M., Stoiber, H. & Katinger, H.W. (2004). Passive
immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. Journal of Antimicrobial
Chemotherapy 54, 915–920.
Trkola, A., Kuster, H., Rusert, P., Joos, B., Fischer,
M., Leemann, C., Manrique, A., Huber, M., Rehr, M.,
Oxenius, A., Weber, R., Stiegler, G., Vcelar, B., Katinger, H., Aceto, L. & Günthard, H.F. (2005). Delay
of HIV-1 rebound after cessation of antiretroviral
therapy through passive transfer of human neutralizing antibodies. Nature Medicine 11, 615–622.
Van der Ryst, E. (2002). Progress in HIV vaccine
research. Oral Diseases 8, Suppl. 2, 21–26.
Duerr, A., Wasserheit, J.N. & Corey, L. (2006). HIV
vaccines: new frontiers in vaccine development.
Clinical Infectious Diseases 43, 500–511.
Young, K.R., McBurney, S.P., Karkhanis, L.U. &
Ross, T.M. (2006). Virus-like particles: Designing
an effective AIDS vaccine. Methods 40, 98–117.
Jekle, A., Keppler, O.T., De Clercq, E., Schols, D.,
Weinstein, M. & Goldsmith, M.A. (2003). In vivo
evolution of human immunodeficiency virus type 1
toward increased pathogenicity through CXCR4mediated killing of uninfected CD4 T cells. Journal
of Virology 77, 5846–5854.
Whitney, J.B. & Ruprecht, R.M. (2004). Live attenuated HIV vaccines: pitfalls and prospects. Current
Opinion in Infectious Diseases 17, 17–26.
PRNewswire (2007). Orchestra Therapeutics Discontinues Its HIV Vaccine Development Program. Available at: http://www.prnewswire. com/cgi-bin/stories.
pl? ACCT=104&STORY=/www/story/07-17-2007/

Role of chimpanzees in AIDS vaccine research

35.

36.

37.

38.
39.

40.

41.

42.

43.
44.

45.

46.

0004627569&EDATE= (Accessed 03.04.08).
da Silva, L.J. & Richtmann, R. (2006). Vaccines
under development: group B streptococcus, herpeszoster, HIV, malaria and dengue. Jornal de Pediatria 82, Suppl., S115–S124.
Gibbs, C.J. Jr, Peters, R., Gravell, M., Johnson,
B.K., Jensen, F.C., Carlo, D.J. & Salk, J. (1991).
Observations after human immunodeficiency virus
immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. Proceedings of the National Academy of
Sciences of the USA 88, 3348–3352.
Niedrig, M., Gregersen, J.P., Fultz, P.N., Bröker,
M., Mehdi, S. & Hilfenhaus, J. (1993). Immune
response of chimpanzees after immunization with
the inactivated whole immunodeficiency virus
(HIV-1), three different adjuvants and challenge.
Vaccine 11, 67–74.
Nigam, P.K. & Kerketta, M. (2006). AIDS vaccine:
present status and future challenges. Indian Journal
of Dermatology, Venereology & Leprology 72, 8–18.
Chakrabarti, B.K., Kong, W.P., Wu, B.Y., Yang,
Z.Y., Friborg, J., Ling, X., King, S.R., Montefiori,
D.C. & Nabel, G.J. (2002). Modifications of the
human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. Journal of Virology 76, 5357–5368.
Berman, P.W., Gregory, T.J., Riddle, L., Nakamura,
G.R., Champe, M.A., Porter, J.P., Wurm, F.M.,
Hershberg, R.D., Cobb, E.K. & Eichberg, J.W. (1990).
Protection of chimpanzees from infection by HIV-1
after vaccination with recombinant glycoprotein
gp120 but not gp160. Nature, London 345, 622–625.
Berman, P.W., Murthy, K.K., Wrin, T., Vennari, J.C.,
Cobb, E.K., Eastman, D.J., Champe, M., Nakamura,
G.R., Davison, D., Powell, M.F., Bussiere, J., Francis,
D.P., Matthews, T., Gregory, T.J. & Obijeski, J.F.
(1996). Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary
isolate of human immunodeficiency virus type 1.
Journal of Infectious Diseases 173, 52–59.
el-Amad, Z., Murthy, K.K., Higgins, K., Cobb, E.K.,
Haigwood, N.L., Levy, J.A. & Steimer, K.S. (1995).
Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2. AIDS
9, 1313–1322.
Cohen, J. (2003). AIDS vaccine trial produces disappointment and confusion. Science, New York
299, 1290–1291.
Mannhalter, J.W., Pum, M., Wolf, H.M., Küpcü, Z.,
Barrett, N., Dorner, F., Eder, G. & Eibl, M.M.
(1991). Immunization of chimpanzees with the
HIV-1 glycoprotein gp160 induces long-lasting Tcell memory. AIDS Research & Human Retroviruses 7, 485–493.
Bruck, C., Thiriart, C., Fabry, L., Francotte, M.,
Pala, P., Van Opstal, O., Culp, J., Rosenberg, M.,
De Wilde, M., Heidt, P. & Heeney, J. (1994). HIV-1
envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
Vaccine 12, 1141–1148.
Girard, M., Kieny, M.P., Pinter, A., Barre-Sinoussi,
F., Nara, P., Kolbe, H., Kusumi, K., Chaput, A.,
Reinhart, T., Muchmore, E., Ronco, J., Kaczorek,
M., Gomard, E., Gluckman, J.C. & Fultz, P.N.
(1991). Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy
of Sciences of the USA 88, 542–546.

423

47.

48.

49.

50.
51.

52.

53.
54.
55.

56.
57.
58.

59.

60.

Girard, M., Meignier, B., Barre-Sinoussi, F., Kieny,
M.P., Matthews, T., Muchmore, E., Nara, P.L.,
Wei, Q., Rimsky, L., Weinhold, K. & Fultz, P.N.
(1995). Vaccine-induced protection of chimpanzees
against infection by a heterologous human immunodeficiency virus type 1. Journal of Virology 69,
6239–6248.
Fultz, P.N., Nara, P., Barre-Sinoussi, F., Chaput,
A., Greenberg, M.L., Muchmore, E., Kieny, M.P. &
Girard, M. (1992). Vaccine protection of chimpanzees against challenge with HIV-1-infected
peripheral blood mononuclear cells. Science, New
York 256, 1687–1690.
Neurath, A.R., Jiang, S., Strick, N., Kolbe, H., Kieny,
M.P., Muchmore, E. & Girard, M. (1991). Antibody
responses of chimpanzees immunized with synthetic
peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. AIDS
Research & Human Retroviruses 7, 813–823.
Girard, M. (1995). Present status of vaccination
against HIV-1 infection. International Journal of
Immunopharmacology 17, 75–78.
The rgp120 HIV Vaccine Study Group (2005).
Placebo-controlled Phase 3 trial of a recombinant
glycoprotein 120 vaccine to prevent HIV-1 infection. Journal of Infectious Diseases 191, 654–665.
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D.,
Tappero, J.W. & Choopanya, K.; Bangkok Vaccine
Evaluation Group (2006). Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent
recombinant glycoprotein 120 HIV-1 vaccine
among injection drug users in Bangkok, Thailand.
Journal of Infectious Diseases 194, 1661–1671.
Tonks, A. (2007). Quest for the AIDS vaccine. British Medical Journal 334, 1346–1348.
Puls, R.L. & Emery, S. (2006). Therapeutic vaccination against HIV: current progress and future
possibilities. Clinical Science 110, 59–71.
Kahn, P. (2005). AIDS vaccine approaches in development. In AIDS Vaccine Handbook (ed. P. Kahn),
Chapter 7, pp. 45–51. New York, NY, USA: AIDS
Vaccine Advocacy Coalition (AVAC).
D’Souza, M.P., Allen, M., Sheets, R. & Johnston, M.I.
(2004). Current advances in HIV vaccines. Current
HIV/AIDS Reports 1, 18–24.
Excler, J.L. (2005). AIDS vaccine development: perspectives, challenges & hopes. Indian Journal of
Medical Research 121, 568–581.
BenMohamed, L., Gras-Masse, H., Tartar, A.,
Daubersies, P., Brahimi, K., Bossus, M., Thomas,
A. & Druilhe, P. (1997). Lipopeptide immunization
without adjuvant induces potent and long-lasting
B, T helper, and cytotoxic T lymphocyte responses
against a malaria liver stage antigen in mice and
chimpanzees. European Journal of Immunology
27, 1242–1253.
Peters, B.S., Cheingsong-Popov, R., Callow, D.,
Foxall, R., Patou, G., Hodgkin, K. & Weber, J.N.
(1997). A pilot phase II study of the safety and
immunogenicity of HIV p17/p24:VLP (p24-VLP) in
asymptomatic HIV seropositive subjects. Journal
of Infection 35, 231–235.
Lindenburg, C.E., Stolte, I., Langendam, M.W.,
Miedema, F., Williams, I.G., Colebunders, R., Weber,
J.N., Fisher, M. & Coutinho, R.A. (2002). Long-term
follow-up: no effect of therapeutic vaccination with
HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 20, 2343–2347.

424

61.

62.

63.
64.

65.

66.

67.

68.

69.
70.

71.

72.

J. Bailey

Kelleher, A.D., Roggensack, M., Jaramillo, A.B.,
Smith, D.E., Walker, A., Gow, I., McMurchie, M.,
Harris, J., Patou, G. & Cooper, D.A. (1998). Safety
and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS 12, 175–182.
Wolff, J.A., Malone, R.W., Williams, P., Chong, W.,
Acsadi, G., Jani, A. & Felgner, P.L. (1990). Direct
gene transfer into mouse muscle in vivo. Science,
New York 247, 1465–1468.
Tang, D.C., DeVit, M. & Johnston, S.A. (1992). Genetic immunization is a simple method for eliciting an
immune response. Nature, London 356, 152–154.
Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes,
G.H., Felgner, P.L., Dwarki, V.J., Gromkowski, S.H.,
Deck, R.R., DeWitt, C.M., Friedman, A., Hawe, L.A.,
Leander, K.R., Martinez, D., Perry, H.C., Shiver,
J.W., Montgomery, D.L. & Liu, M.A. (1993). Heterologous protection against influenza by injection of
DNA encoding a viral protein. Science, New York
259, 1745–1749.
Wang, B., Ugen, K.E., Srikantan, V., Agadjanyan,
M.G., Dang, K., Refaeli, Y., Sato, A.I., Boyer, J.,
Williams, W.V. & Weiner, D.B. (1993). Gene inoculation generates immune responses against human
immunodeficiency virus type 1. Proceedings of the
National Academy of Sciences of the USA 90, 4156–
4160.
MacGregor, R.R., Boyer, J.D., Ugen, K.E., Lacy,
K.E., Gluckman, S.J., Bagarazzi, M.L., Chattergoon,
M.A., Baine, Y., Higgins, T.J., Ciccarelli, R.B., Coney,
L.R., Ginsberg, R.S. & Weiner, D.B. (1998). First
human trial of a DNA-based vaccine for treatment of
human immunodeficiency virus type 1 infection:
safety and host response. Journal of Infectious
Diseases 178, 92–100.
Calarota, S., Bratt, G., Nordlund, S., Hinkula, J.,
Leandersson, A.C., Sandström, E. & Wahren, B.
(1998). Cellular cytotoxic response induced by DNA
vaccination in HIV-1-infected patients. Lancet 351,
1320–1325.
Calarota, S.A., Leandersson, A.C., Bratt, G., Hinkula, J., Klinman, D.M., Weinhold, K.J., Sandström,
E. & Wahren, B. (1999). Immune responses in
asymptomatic HIV-1-infected patients after HIVDNA immunization followed by highly active antiretroviral treatment. Journal of Immunology 163,
2330–2338.
Letvin, N.L. (2006). Progress and obstacles in the
development of an AIDS vaccine. Nature Reviews:
Immunology 6, 930–939.
Luzuriaga, K., Newell, M.L., Dabis, F., Excler, J.L.
& Sullivan, J.L. (2006). Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and
logistical priorities. Lancet 368, 511–521.
Boyer, J.D., Ugen, K.E., Wang, B., Agadjanyan, M.,
Gilbert, L., Bagarazzi, M.L., Chattergoon, M.,
Frost, P., Javadian, A., Williams, W.V., Refaeli, Y.,
Ciccarelli, R.B., McCallus, D., Coney, L. & Weiner,
D.B. (1997). Protection of chimpanzees from highdose heterologous HIV-1 challenge by DNA vaccination. Nature Medicine 3, 526–532.
Boyer, J.D., Cohen, A.D., Ugen, K.E., Edgeworth,
R.L., Bennett, M., Shah, A., Schumann, K., Nath,
B., Javadian, A., Bagarazzi, M.L., Kim, J. &
Weiner, D.B. (2000). Therapeutic immunization of
HIV-infected chimpanzees using HIV-1 plasmid
antigens and interleukin-12 expressing plasmids.
AIDS 14, 1515–1522.

73.
74.

75.

76.

77.
78.

79.

80.

81.

82.

83.
84.

85.

Kennedy, R.C. (1997). DNA vaccination for HIV.
Nature Medicine 3, 501–502.
Ugen, K.E., Boyer, J.D., Wang, B., Bagarazzi, M.,
Javadian, A., Frost, P., Merva, M.M., Agadjanyan,
M.G., Nyland, S., Williams, W.V., Coney, L.,
Ciccarelli, R. & Weiner, D.B. (1997). Nucleic acid
immunization of chimpanzees as a prophylactic/
immunotherapeutic vaccination model for HIV-1:
prelude to a clinical trial. Vaccine 15, 927–930.
Barouch, D.H., Santra, S., Steenbeke, T.D., Zheng,
X.X., Perry, H.C., Davies, M.E., Freed, D.C., Craiu,
A., Strom, T.B., Shiver, J.W. & Letvin, N.L. (1998).
Augmentation and suppression of immune
responses to an HIV-1 DNA vaccine by plasmid
cytokine/Ig administration. Journal of Immunology 161, 1875–1882.
Barouch, D.H., Santra, S., Schmitz, J.E., Kuroda,
M.J., Fu, T.M., Wagner, W., Bilska, M., Craiu, A.,
Zheng, X.X., Krivulka, G.R., Beaudry, K., Lifton,
M.A., Nickerson, C.E., Trigona, W.L., Punt, K.,
Freed, D.C., Guan, L., Dubey, S., Casimiro, D.,
Simon, A., Davies, M.E., Chastain, M., Strom, T.B.,
Gelman, R.S., Montefiori, D.C., Lewis, M.G.,
Emini, E.A., Shiver, J.W. & Letvin, N.L. (2000).
Control of viremia and prevention of clinical AIDS
in rhesus monkeys by cytokine-augmented DNA
vaccination. Science, New York 290, 486–492.
Wells, D.J. (2004). Gene therapy progress and
prospects: electroporation and other physical methods. Gene Therapy 11, 1363–1369.
Martin, B., Sainlos, M., Aissaoui, A., Oudrhiri, N.,
Hauchecorne, M., Vigneron, J.P., Lehn, J.M. & Lehn,
P. (2005). The design of cationic lipids for gene delivery. Current Pharmaceutical Design 11, 375–394.
Calarota, S.A. & Weiner, D.B. (2004). Approaches
for the design and evaluation of HIV-1 DNA vaccines. Expert Review of Vaccines 3, Suppl. 4,
S135–S149.
Giri, M., Ugen, K.E. & Weiner, D.B. (2004). DNA
vaccines against human immunodeficiency virus
type 1 in the past decade. Clinical Microbiology
Reviews 17, 370–389.
Flynn, N.M., Forthal, D.N., Harro, C.D., Judson,
F.N., Mayer, K.H. & Para, M.F. (2005). Placebocontrolled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
Journal of Infectious Diseases 191, 654–665.
Gilbert, P.B., Peterson, M.L., Follmann, D., Hudgens, M.G., Francis, D.P., Gurwith, M., Heyward,
W.L., Jobes, D.V., Popovic, V., Self, S.G., Sinangil, F.,
Burke, D. & Berman, P.W. (2005). Correlation
between immunologic responses to a recombinant
glycoprotein 120 vaccine and incidence of HIV-1
infection in a phase 3 HIV-1 preventive vaccine trial.
Journal of Infectious Diseases 191, 666–677.
Graham, B.S. & Mascola, J.R. (2005). Lessons from
failure: preparing for future HIV-1 vaccine efficacy
trials. Journal of Infectious Diseases 191, 647–649.
Peng, B., Wang, L.R., Gómez-Román, V.R., DavisWarren, A., Montefiori, D.C., Kalyanaraman, V.S.,
Venzon, D., Zhao, J., Kan, E., Rowell, T.J., Murthy,
K.K., Srivastava, I., Barnett, S.W. & RobertGuroff, M. (2005). Replicating rather than nonreplicating adenovirus-human immunodeficiency
virus recombinant vaccines are better at eliciting
potent cellular immunity and priming high-titer
antibodies. Journal of Virology 79, 10,200–10,209.
Shiver, J.W., Fu, T.M., Chen, L., Casimiro, D.R.,
Davies, M.E., Evans, R.K., Zhang, Z.Q., Simon, A.J.,

Role of chimpanzees in AIDS vaccine research

86.

87.

88.

89.

90.

91.

92.
93.

Trigona, W.L., Dubey, S.A., Huang, L., Harris, V.A.,
Long, R.S., Liang, X., Handt, L., Schleif, W.A., Zhu,
L., Freed, D.C., Persaud, N.V., Guan, L., Punt, K.S.,
Tang, A., Chen, M., Wilson, K.A., Collins, K.B.,
Heidecker, G.J., Fernandez, V.R., Perry, H.C., Joyce,
J.G., Grimm, K.M., Cook, J.C., Keller, P.M., Kresock,
D.S., Mach, H., Troutman, R.D., Isopi, L.A., Williams, D.M., Xu, Z., Bohannon, K.E., Volkin, D.B.,
Montefiori, D.C., Miura, A., Krivulka, G.R., Lifton,
M.A., Kuroda, M.J., Schmitz, J.E., Letvin, N.L.,
Caulfield, M.J., Bett, A.J., Youil, R., Kaslow, D.C. &
Emini, E.A. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature, London 415,
331–335.
Natuk, R.J., Lubeck, M.D., Chanda, P.K., Chengalvala, M., Wade, M.S., Murthy, S.C., Wilhelm, J.,
Vernon, S.K., Dheer, S.K., Mizutani, S., Lee, S.,
Murthy, K.K., Eichberg, J.W., Davis, A.R. & Hung,
P.P. (1993). Immunogenicity of recombinant human
adenovirus-human immunodeficiency virus vaccines
in chimpanzees. AIDS Research & Human Retroviruses 9, 395–404.
Lubeck, M.D., Natuk, R.J., Chengalvala, M.,
Chanda, P.K., Murthy, K.K., Murthy, S., Mizutani,
S., Lee, S.G., Wade, M.S., Bhat, B.M., Bhat, R.,
Dheer, S.K., Eichberg, J.W., Davis, A.R. & Hung,
P.P.(1994). Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in
chimpanzees following intranasal administration.
AIDS Research & Human Retroviruses 10, 1443–
1449.
Xiang, Z., Gao, G., Reyes-Sandoval, A., Cohen, C.J.,
Li, Y., Bergelson, J.M., Wilson, J.M. & Ertl, H.C.
(2002). Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to
a transgene product. Journal of Virology 76, 2667–
2675.
Lubeck, M.D., Natuk, R., Myagkikh, M., Kalyan,
N., Aldrich, K., Sinangil, F., Alipanah, S., Murthy,
S.C., Chanda, P.K., Nigida, S.M. Jr, Markham,
P.D., Zolla-Pazner, S., Steimer, K., Wade, M.,
Reitz, M.S. Jr, Arthur, L.O., Mizutani, S., Davis, A.,
Hung, P.P., Gallo, R.C., Eichberg, J. & RobertGuroff, M. (1997). Long-term protection of chimpanzees against high-dose HIV-1 challenge induced
by immunization. Nature Medicine 3, 651–658.
Robert-Guroff, M., Kaur, H., Patterson, L.J., Leno,
M., Conley, A.J., McKenna, P.M., Markham, P.D.,
Richardson, E., Aldrich, K., Arora, K., Murty, L.,
Carter, L., Zolla-Pazner, S. & Sinangil, F. (1998).
Vaccine protection against a heterologous, nonsyncytium-inducing, primary human immunodeficiency virus. Journal of Virology 72, 10,275–
10,280.
Zolla-Pazner, S., Lubeck, M., Xu, S., Burda, S.,
Natuk, R.J., Sinangil, F., Steimer, K., Gallo, R.C.,
Eichberg, J.W., Matthews, T. & Robert-Guroff, M.
(1998). Induction of neutralizing antibodies to Tcell line-adapted and primary human immunodeficiency virus isolates with a prime–boost vaccine
regimen in chimpanzees. Journal of Virology 72,
1052–1059.
Altman, L.K. & Pollack, A. (2007). Failure of Vaccine Test Is Setback in AIDS Fight. New York Times,
22.09.07.
Merck (2007). Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck’s Investigational HIV Vaccine Candidate. Interim Analysis

425

of STEP Study Shows Vaccine was Not Effective.
Press release of 21.09.07. Available at: http://www.
merck.com/newsroom/press_releases/research_and
_development/2007_0921.html (Accessed 03.04.08).
94. Cohen, J. (2007). AIDS research. Did Merck’s failed
HIV vaccine cause harm? Science, New York 318,
1048–1049.
95. Santra, S., Seaman, M.S., Xu, L., Barouch, D.H.,
Lord, C.I., Lifton, M.A., Gorgone, D.A., Beaudry,
K.R., Svehla, K., Welcher, B., Chakrabarti, B.K.,
Huang, Y., Yang, Z.Y., Mascola, J.R., Nabel, G.J. &
Letvin, N.L. (2005). Replication-defective adenovirus serotype 5 vectors elicit durable cellular and
humoral immune responses in nonhuman primates. Journal of Virology 79, 6516–6522.
96. Jaoko, W.G., Omosa, G., Bhatt, K., Matu, L.,
Ogutu, H., Wakasiaka, S., Odada, J., Anzala, O.,
Bashir, F., Oyaro, M., Indangasi, J., NdinyaAchola, J., Schmidt, C., Hanke, T., McMichael, A.,
Fast, P. & Bwayo, J. (2004). Safety and immunogenicity of DNA and MVA HIVA vaccines in phase
I HIV-1 vaccine trials in Nairobi, Kenya [Abstract
54]. In Program and Abstracts of AIDS Vaccine
2004 (Lausanne, Switzerland), p. 33.
97. Clements-Mann, M.L., Weinhold, K., Matthews, T.J.,
Graham, B.S., Gorse, G.J., Keefer, M.C., McElrath,
M.J., Hsieh, R-H., Mestecky, J., Zolla-Pazner, S.,
Mascola, J., Schwartz, D., Siliciano, R., Corey, L.,
Wright, P.F., Belshe, R., Dolin, R., Jackson, S., Xu,
S., Fast, P., Walker, M.C., Stablein, D., Excler, J-L.,
Tartaglia, J., Duliege, A-M., Sinangil, F., Paoletti, E.
& the NIAID AIDS Vaccine Evaluation Group
(1998). Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox
expressing HIV-1MN gp120, HIV-1SF2 recombinant
gp120, or both vaccines in seronegative adults. The
Journal of Infectious Diseases 177, 1230–1246.
98. Belshe, R.B., Stevens, C., Gorse, G.J., Buchbinder,
S., Weinhold, K., Sheppard, H., Stablein, D., Self,
S., McNamara, J., Frey, S., Flores, J., Excler, J-L.,
Klein, M., Habib, R.E., Duliege, A-M., Harro, C.,
Corey, L., Keefer, M., Mulligan, M., Wright, P.,
Celum, C., Judson, F., Mayer, K., McKirnan, D.,
Marmor, M., Woody, G.; the National Institute of
Allergy and Infectious Diseases AIDS Vaccine
Evaluation Group and HIV Network for Prevention
Trials (HIVNET) (2001). Safety and immunogenicity
of a canarypox-vectored human immunodeficiency
virus Type 1 vaccine with or without gp120: a phase
2 study in higher- and lower-risk volunteers. The
Journal of Infectious Diseases 183, 1343–1352.
99. Moss, B. (1990). Poxviridae and their replication.
In Virology 1990 (ed. N. Fields & D.M. Knipe), pp.
2079–2111. New York, NY, USA: Raven Press.
100. Evans, T.G., Keefer, M.C., Weinhold, K.J., Wolff,
M., Montefiori, D., Gorse, G.J., Graham, B.S.,
McElrath, M.J., Clements-Mann, M.L., Mulligan,
M.J., Fast, P., Walker, M.C., Excler, J-L., Duliege,
A-M., Tartaglia, J. & the NIAID AIDS Vaccine
Evaluation Group (1999). A canarypox vaccine
expressing multiple human immunodeficiency
virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte
responses in seronegative volunteers. The Journal
of Infectious Diseases 180, 290–298.
101. Berencsi, K., Gyulai, Z., Gönczöl, E., Pincus, S., Cox,
W.I., Michelson, S., Kari, L., Meric, C., Cadoz, M.,
Zahradnik, J., Starr, S. & Plotkin, S. (2001). A
canarypox vector-expressing cytomegalovirus (CMV)

426

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

J. Bailey

phosphoprotein 65 induces long-lasting cytotoxic T
cell responses in human CMV-seronegative subjects.
The Journal of Infectious Diseases 183, 1171–1179.
Bernstein, D.I., Schleiss, M.R., Berencsi, K., Gönczöl,
E., Dickey, M., Khoury, P., Cadoz, M., Meric, C.,
Zahradnik, J., Duliege, A.M. & Plotkin, S. (2002).
Effect of previous or simultaneous immunization
with canarypox expressing cytomegalovirus (CMV)
glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
The Journal of Infectious Diseases 185, 686–690.
Tubiana, R., Gomard, E., Fleury, H., Gougeon, M.L.,
Mouthon, B., Picolet, H. & Katlama, C. (1997).
Vaccine therapy in early HIV-1 infection using a
recombinant canarypox virus expressing gp160MN
(ALVAC-HIV): a double-blind controlled randomized
study of safety and immunogenicity. AIDS 11,
819–820.
Franchini, G., Gurunathan, S., Baglyos, L., Plotkin,
S. & Tartaglia, J. (2004). Poxvirus based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Review of
Vaccines 3, S75–S88.
Johnson, D.C., McFarland, E.J., Muresan, P.,
Fenton, T., McNamara, J., Read, J.S., Hawkins, E.,
Bouquin, P.L., Estep, S.G., Tomaras, G.D., Vincent,
C.A., Rathore, M., Melvin, A.J., Gurunathan, S. &
Lambert, J. (2005). Safety and immunogenicity of an
HIV-1 recombinant canarypox vaccine in newborns
and infants of HIV-1-infected women. The Journal of
Infectious Diseases 192, 2129–2133.
Grassi, F., Hosmalin, A., McIlroy, D., Calvez, V.,
Debré, P. & Autran, B. (1999). Depletion in blood
CD11c-positive dendritic cells from HIV-infected
patients. AIDS 13, 759–766.
Kalams, S.A., Goulder, P.J., Shea, A.K., Jones, N.G.,
Trocha, A.K., Ogg, G.S. & Walker, B.D. (1999).
Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory
responses decline after suppression of viremia with
highly active antiretroviral therapy. Journal of
Virology 73, 6721–6728.
Pitcher, C.J., Quittner, C., Peterson, D.M., Connors, M., Koup, R.A., Maino, V.C. & Picker, L.J.
(1999). HIV-1-specific CD4+ T cells are detectable
in most individuals with active HIV-1 infection, but
decline with prolonged viral suppression. Nature
Medicine 5, 518–525.
Donaghy, H., Pozniak, A., Gazzard, B., Qazi, N.,
Gilmour, J., Gotch, F. & Patterson, S. (2001). Loss
of blood CD11c+ myeloid and CD11c– plasmacytoid
dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98,
2574–2576.
Lu, W., Arraes, L.C., Ferreira, W.T. & Andrieu,
J.M. (2004). Therapeutic dendritic-cell vaccine for
chronic HIV-1 infection. Nature Medicine 10,
1359–1365.
Barratt-Boyes, S.M., Henderson, R.A. & Finn, O.J.
(1996). Chimpanzee dendritic cells with potent
immunostimulatory function can be propagated
from peripheral blood. Immunology 87, 528–534.
Barratt-Boyes, S.M., Kao, H. & Finn, O.J. (1997).
Chimpanzee dendritic cells derived in vitro from
blood monocytes and pulsed with antigen elicit specific immune responses in vivo. Journal of
Immunotherapy 21, 142–148.
Folgori, A., Capone, S., Ruggeri, L., Meola, A.,
Sporeno, E., Ercole, B.B., Pezzanera, M., Tafi, R.,

114.

115.
116.

117.
118.

119.
120.
121.

122.
123.

124.
125.
126.

127.

128.

Arcuri, M., Fattori, E., Lahm, A., Luzzago, A., Vitelli,
A., Colloca, S., Cortese, R. & Nicosia, A. (2006). A Tcell HCV vaccine eliciting effective immunity against
heterologous virus challenge in chimpanzees. Nature
Medicine 12, 190–197.
Goujard, C., Marcellin, F., Hendel-Chavez, H.,
Burgard, M., Meiffrédy, V., Venet, A., Rouzioux, C.,
Taoufik, Y., El Habib, R., Beumont-Mauviel, M.,
Aboulker, J.P., Lévy, Y., Delfraissy, J.F.; the PRIMOVAC-ANRS 095 Study Group (2007). Interruption of antiretroviral therapy initiated during
primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2
compared with IL-2 alone in the ANRS 095
Randomized Study. AIDS Research & Human Retroviruses 23, 1105–1113.
Singh, M. (2006). No vaccine against HIV yet — are
we not perfectly equipped? Virology Journal 3, 60.
Locher, C.P., Grant, R.M., Collisson, E.A., ReyesTerán, G., Elbeik, T., Kahn, J.O. & Levy, J.A.
(1999). Antibody and cellular immune responses in
breakthrough infection subjects after HIV type 1
glycoprotein 120 vaccination. AIDS Research &
Human Retroviruses 15, 1685–1689.
Johnston, M.I. (2000). The role of nonhuman primate models in AIDS vaccine development.
Molecular Medicine Today 67, 267–270.
BUAV (2006). Still Dying of Ignorance? 25 Years of
Failed Primate AIDS Research, 16pp. London, UK:
BUAV. Available at: http://www.buav.org/downloads/
pdf/BUAV_Report-AIDs.pdf (Accessed 03.04.08).
Hu, S.L. (2005). Non-human primate models for
AIDS vaccine research. Current drug targets.
Infectious Disorders 5, 193–201.
Levy, Y. (2005). Therapeutic HIV vaccines: an
update. Current HIV/AIDS Reports 2, 5–9.
Tonini, T., Barnett, S., Donnelly, J. & Rappuoli, R.
(2005). Current approaches to developing a preventative HIV vaccine. Current Opinion in Investigational Drugs 6, 155–162.
Fauci, A.S. & Fischinger, P.J. (1988). The development of an AIDS vaccine: progress and promise.
Public Health Reports 1033, 230–236.
Wyand, M.S. (1992). The use of SIV-infected rhesus
monkeys for the preclinical evaluation of AIDS
drugs and vaccines. AIDS Research & Human
Retroviruses 8, 349–356.
Desrosiers, R.C. & Bolognesi, D.P. (1994). Controversies in science: a live virus AIDS vaccine?
Journal of NIH Research 6, 54–62.
Cohen, J. (2007). Biomedical research. The
endangered lab chimp. Science, New York 315,
450–452.
Ondoa, P., Vereecken, C., Fransen, K., Colebunders, R., van der Groen, G., Heeney, J.L. & Kestens,
L. (2003). Human and simian immunodeficiency
virus-infected chimpanzees do not have increased
intracellular levels of beta-chemokines in contrast
to infected humans. Journal of Medical Virology
693, 297–305.
Kestens, L., Vingerhoets, J., Peeters, M., Vanham,
G., Vereecken, C., Penne, G., Niphuis, H., van Eerd,
P., van der Groen, G., Gigase, P. & Heeney, J. (1995).
Phenotypic and functional parameters of cellular
immunity in a chimpanzee with a naturally acquired
simian immunodeficiency virus infection. The
Journal of Infectious Diseases 172, 957–963.
Novembre, F.J., Saucier, M., Anderson, D.C.,
Klumpp, S.A., O’Neil, S.P., Brown, C.R. 2nd, Hart,

Role of chimpanzees in AIDS vaccine research

129.
130.
131.

132.

133.

134.

135.
136.
137.
138.
139.

140.

141.

142.

143.

144.

145.
146.

C.E., Guenthner, P.C., Swenson, R.B. & McClure,
H.M. (1997). Development of AIDS in a chimpanzee infected with human immunodeficiency
virus type 1. Journal of Virology 715, 4086–4091.
Sibal, L.R. & Samson, K.J (2001). Nonhuman primates: a critical role in current disease research.
ILAR Journal 422, 74–84.
Svendsen, P. & Hau, J. (1994). Animal Models. In
Handbook of Laboratory Animal Science, Vol. 2,
224pp. Boca Raton, FL, USA: CRC Press.
NIH Aids Research Program Evaluation Task Force
(1997). Etiology and Pathogenesis Area Review Panel
Report. Available at: http://www.nih.gov/news/
AIDS-panel/ETIOLOGY.HTML (Accessed 18.06.08).
Smaglik, P. (1999). AIDS vaccine researchers turn
from chimps to monkeys. The Scientist 13, 7.
Available at: http://www.lclark.edu/org/ncal/objects/
AIDvaccine.htm (Accessed 03.04.08).
Nath, B.M., Schumann, K.E. & Boyer, J.D. (2000).
The chimpanzee and other non-human-primate
models in HIV-1 vaccine research. Trends in
Microbiology 89, 426–431.
National Resource Council (NRC), Institute for
Laboratory Animal Research (1997). Chimpanzees
in Research: Strategies for their Ethical Care, Management, and Use, 108pp. Washington, DC, USA:
National Academy Press.
Preston-Mafham, R. & Preston-Mafham, K. (1992).
Primates of the World, 192pp. New York, NY, USA:
Facts on File.
Bright, M. (1994). Intelligence in Animals, 160pp.
London, UK: Toucan Books/Reader’s Digest.
Stanford, C. (1995). Chimpanzee hunting behavior
and human evolution. American Scientist (May–
June), 256–261.
Ross, B. (1998). The Human–Chimp Connection.
Available at: www.benross.net/chimp.htm (Accessed 18.06.08).
Briggs, H. (2001). Cultural Habits of Chimps. BBC
News Online, 10 August, 2001. Available at: http://
news.bbc.co.uk/1/low/sci/tech/1484261.stm (Accessed 03.04.08).
Jane Goodall Institute (Undated). So Like Us.
Available at: http://www.janegoodall.org/chimp_
central/chimpanzees/similarities/like_us.asp
(Accessed 03.04.08).
Jane Goodall Institute (Undated). Communication.
Available at: http://www.janegoodall.org/chimp_
central/chimpanzees/behavior/communication.asp
(Accessed 03.04.08).
Jane Goodall Institute (Undated). Similarities
Between Chimpanzees and Human Beings. Available at: http://www.janegoodall.org/chimp_central/
chimpanzees/similarities/default.asp (Accessed
03.04.08).
Brüne, M., Brüne-Cohrs, U., McGrew, W.C. & Preuschoft, S. (2006). Psychopathology in great apes:
Concepts, treatment options and possible homologies
to human psychiatric disorders. Neuroscience &
Biobehavioral Reviews 308, 1246–1259.
Bradshaw, G.A., Capaldo, T., Lindner, L. & Grow,
G. (2008). Building an inner sanctuary: complex
PTSD in chimpanzees. Journal of Trauma & Dissociation 9, 9–34.
Goodall, J. (1998). Essays on science and society:
Learning from the chimpanzees: a message humans
can understand. Science, New York 282, 2184–2185.
Prince, A.M., Horowitz, B., Baker, L., Shulman,
R.W., Ralph, H., Valinsky, J., Cundell, A., Brotman,

427

147.

148.

149.

150.

151.

152.

153.

154.

155.

B., Boehle, W., Rey, F., Piet, M., Reesink, H., Lelie,
N., Tersmette, M., Miedema, F., Barbosa, L., Nemo,
G., Nastala, C.L., Allan, J.S., Lee, D.R. & Eichberg,
J.W. (1988). Failure of a human immunodeficiency
virus (HIV) immune globulin to protect chimpanzees
against experimental challenge with HIV. Proceedings of the National Academy of Sciences of the
USA 85, 6944–6948.
Wang, C-Y., Sawyer, L.S.W., Murthy, K.K., Fang, X.,
Walfield, A.M., Ye, J., Wang, J.J.G., Chen, P-D., Li,
M-L., Salas, M.T., Shen, M., Gauduin, M-C., Boyle,
R.W., Koup, R.A., Montefiori, D.C., Mascola, J.R.,
Koff, W.C. & Hanson, C.V. (1999). Postexposure
immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proceedings of the
National Academy of Sciences of the USA 96, 10,367–
10,372.
Berman, P.W., Groopman, J.E., Gregory, T., Clapham, P.R., Weiss, R.A., Ferriani, R., Riddle, L.,
Shimasaki, C., Lucas, C., Lasky, L.A. & Eichberg,
J.W. (1988). Human immunodeficiency virus type 1
challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proceedings of the
National Academy of Sciences of the USA 85,
5200–5204.
Arthur, L.O., Bess, J.W. Jr, Waters, D.J., Pyle,
S.W., Kelliher, J.C., Nara, P.L., Krohn, K., Robey,
W.G., Langlois, A.J., Gallo, R.C. & Fischinger, P.J.
(1989). Challenge of chimpanzees (Pan troglodytes)
immunized with human immunodeficiency virus
envelope glycoprotein gp120. Journal of Virology
63, 5046–5053.
Balla-Jhagjhoorsingh, S.S., Mooij, P., ten Haaft,
P.J.F., Bogers, W.M.J.M., Teeuwsen, V.J.P., Koopman, G. & Heeney, J.L. (2001). Protection from
secondary human immunodeficiency virus type 1
infection in chimpanzees suggests the importance
of antigenic boosting and a possible role for cytotoxic T cells. The Journal of Infectious Diseases
184, 136–143.
Boyer, J.D., Ugen, K.E., Chattergoon, M., Wang, B.,
Shah, A., Agadjanyan, M., Bagarazzi, M.L., Javadian,
A., Carrano, R., Coney, L., Williams, W.V. & Weiner,
D.B. (1997). DNA vaccination as anti-human
immunodeficiency virus immunotherapy in infected
chimpanzees. The Journal of Infectious Diseases
176, 1501–1509.
Hu, S-L., Fultz, P.N., McClure, H.M., Eichberg, J.W.,
Kinney Thomas, E., Zarling, J., Singhal, M.C.,
Kosowski, S.G., Brent Swenson, R., Anderson, D.C.
& Todaro, G. (1987). Effect of immunization with a
vaccinia-HIV env recombinant on HIV infection of
chimpanzees. Nature 328, 721–723.
Van Eendenburg, J.P., Yagello, M., Girard, M.,
Kieny, M.P., Lecocq, J.P., Muchmore, E., Fultz, P.N.,
Riviere, Y., Montagnier, L. & Gluckman, J.C. (1989).
Cell-mediated immune proliferative responses to
HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. AIDS Research & Human
Retroviruses 5, 41–50.
Lockey, T.D., Slobod, K.S., Caver, T.E., D’Costa, S.,
Owens, R.J., McClure, H.M., Compans, R.W. &
Hurwitz, J.L. (2000). Multi-envelope HIV vaccine
safety and immunogenicity in small animals and
chimpanzees. Immunologic Research 21, 7–21.
Girard, M., van der Ryst, E., Barré-Sinoussi, F.,
Nara, P., Tartaglia, J., Paoletti, E., Blondeau, C.,
Jennings, M., Verrier, F., Meignier, B. & Fultz, P.N.
(1997). Challenge of chimpanzees immunized with a

428

recombinant canarypox-HIV-1 virus. Virology 232,
98–104.
156. Coëffier, E., Girard, M., Barré-Sinoussi, F., Meignier, B., Muchmore, E., Fultz, P.N. & LeClerc, C.

J. Bailey

(1998). Fine specificity of anti-V3 antibodies
induced in chimpanzees by HIV candidate vaccines.
AIDS Research & Human Retroviruses 14, 1023–
1034.

